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 ABSTRACT 
 
Lupus erythematosus (LE) is an autoimmune disease with a wide range of clinical manifestations. This 
spectrum spans from limited cutaneous disease to life-threatening rheumatic disorder involving vital 
organs. Sun exposure is an evident exogenous trigger of both cutaneous (CLE) and systemic LE (SLE). 
CLE-resembling skin lesions can also be experimentally induced using artificial ultraviolet radiation 
(UVR). Skin is an organ which is physically available for clinical observation and biopsy acquisition. 
This provides a possibility to relate the clinical appearance of developing and healing lesions to the 
molecular and cellular events observed in the skin specimens.  
In the studies included in this thesis we aimed to define the molecular regulation of 
cutaneous inflammation in CLE and to evaluate if a standardized photoprovocation is a suitable method 
to study CLE in a multicenter study. Firstly, we explored what cytokines are involved in the regulation of 
inflammation in UVR-induced CLE lesions; secondly, we investigated if the autoantigen Ro52 is 
expressed in UVR-induced and spontaneous CLE lesions and lastly, if UVR and reactive nitrogen species 
(NO) could modulate the expression of autoantigen Ro52 in the LE-target cell keratinocyte. We also 
wanted to examine which domains within the Ro52 protein that determine its subcellular localization, and 
if Ro52 can interact with ubiquitin conjugating enzymes residing in different cell compartments.  
To achieve our goals we used skin biopsy material derived from spontaneously occurring 
CLE lesions, and also a longitudinal collection of cutaneous specimens acquired from experimentally 
UVR-induced LE-specific lesions. We established patient- and healthy control-derived primary 
keratinocyte cultures in order to investigate Ro52 expression under the influence of UVR and NO. 
Furthermore, by constructing green fluorescent protein-Ro52 (GFP-Ro52) mutants and transfecting HeLa 
cells with them, we investigated the sequences of importance for subcellular localization of this 
autoantigen. 
In paper I we demonstrated that a standardized photoprovocation allows inducing CLE-
resembling lesions in approximately half of the patients and is a safe and reproducible method suitable for 
multicenter studies. 
In paper II we demonstrated that HMGB1, an alarmin with cytokine-like functions, is 
upregulated and translocated to the extracellular space in UVR-induced CLE lesions, and that its highest 
expression coincides with the peak of clinical activity of the lesions. Other investigated cytokines TNF-Į 
and IL-1ȕ seemed to be of less importance. 
In paper III we showed that Ro52 is strongly expressed in the epidermis and dermis of 
spontaneous and UVR-induced CLE lesions and is predominantly located in the keratinocyte cytoplasm. 
Moreover, our results of in vitro experiments indicate that UVR can upregulate the expression of this 
autoantigen in the cytoplasm of keratinocytes. 
In paper IV we determined that NO can modulate the subcellular localization of Ro52 in 
human keratinocytes and HeLa cells in vitro. We have also demonstrated that Ro52 is expressed in close 
proximity to iNOS and is located in both cytoplasmic and nuclear compartments of the cells present in 
CLE skin lesions. In addition, we proved that the sequence located within the leucine zipper/coiled coil 
domain of Ro52 is the one that retains the protein in the cell cytoplasm while the B30.2 domain is 
important for the nuclear translocalization of Ro52. We have also demonstrated that Ro52 can interact 
with both nuclear and cytoplasmic ubiquitin conjugating enzymes.   
In conclusion, the studies presented in this thesis provide novel insights into the 
molecular events that occur in the skin of CLE patients during lesion development. Our findings indicate 
that UVR and NO can modulate the expression of the autoantigen Ro52 in keratinocytes, which are the 
target cells of autoimmunity in LE. We demonstrate that standardized photoprovocation is a safe and 
reproducible method to study UVR-induced CLE in multicenter studies. 
  
 
LIST OF PUBLICATIONS 
 
I. Photoprovocation in Cutaneous Lupus Erythematosus: A Multicenter 
Study Evaluating a Standardized Protocol 
A Kuhn, A Wozniacka, JC Szepietowski, R Gläser, P Lehmann, M Haust,  
A Sysa-Jedrzejowska, A Reich, V OKE, R Hügel, C Calderon, DE. de Vries, 
F Nyberg 
Journal of Investigative Dermatology. Accepted for publication, 2011. 
 
II. Translocation of the novel cytokine HMGB1 to the cytoplasm and 
extracellular space coincides with the peak of clinical activity in 
experimentally UV-induced lesions of cutaneous lupus erythematosus 
V BARKAUSKAITE, M Ek, K Popovic, HE Harris, M Wahren-Herlenius 
and F. Nyberg 
Lupus, 2007, 16:794–802 
 
III. High Ro52 expression in spontaneous and UV-induced cutaneous 
inflammation 
V OKE, I Vassilaki, A Espinosa, L Strandberg, VK Kuchroo, F Nyberg and  
M Wahren-Herlenius 
Journal of Investigative Dermatology, 2009, 129:2000-10 
 
IV. The autoantigen Ro52 is an E3 ligase resident in the cytoplasm but enters 
the nucleus upon cellular exposure to nitric oxide 
A Espinosa, V OKE, Å Elfving, F Nyberg, R Covacu, M Wahren-Herlenius 
Experimental cell research, 2008, 314:3605-13 
 
 
In the thesis, the papers are referred to by their Roman numerals.  
 
 CONTENTS 
1 Background .................................................................................................. 1
1.1 Lupus erythematosus.......................................................................... 1
1.1.1 Photosensitivity in LE............................................................ 3
1.1.2 Autoantibodies in LE ............................................................. 4
1.2 Lupus erythematosus and the skin ..................................................... 5
1.2.1 Clinical manifestations and prognosis of CLE subtypes ...... 6
1.2.2 Histo- and immunopathology of CLE................................... 8
1.3 Genetic associations in lupus erythematosus..................................... 9
1.3.1 Genetics of CLE and anti-Ro/SSA positive disease ............. 9
1.4 LE triggering factors ........................................................................ 10
1.4.1 The sun and ultraviolet radiation (UVR)............................. 11
1.4.2 Smoking................................................................................ 13
1.4.3 Gender and sex hormones.................................................... 14
1.4.4 Viral infection ...................................................................... 14
1.4.5 Drugs .................................................................................... 14
2 Autoimmune inflammation in the target organ ......................................... 16
2.1 HMGB1 ............................................................................................ 17
2.1.1 HMGB1 in inflammation..................................................... 18
2.1.2 HMGB1 in autoimmunity.................................................... 18
2.2 Ro52.................................................................................................. 19
2.2.1 The functions of Ro52 ......................................................... 19
2.2.2 The expression of Ro52 ....................................................... 21
2.2.3 Ro52 and interferon (IFN) responses in LE ........................ 21
2.3 Reactive oxygen and nitrogen species (ROS) ................................. 22
3 Aspects of the systemic autoimmune inflammation in LE ....................... 24
3.1 Cell death .......................................................................................... 24
3.2 CRP and anti-CRP antibodies.......................................................... 24
3.3 Complement ..................................................................................... 25
3.4 Phagocytes and recognition of ICs .................................................. 25
3.5 The adaptive immune system in LE ................................................ 26
3.5.1 Dendritic cells (DCs) and LE .............................................. 26
3.5.2 T cells and LE ...................................................................... 27
3.5.3 B cells and LE ...................................................................... 28
4 Aims of the thesis ....................................................................................... 30
5 Results and discussion................................................................................ 31
5.1 Photoprovocation in CLE: a multicenter study ............................... 31
5.1.1 Rationale, background and methodological considerations 31
5.1.2 Multicenter photoprovocation study.................................... 34
5.1.3 Discussion ............................................................................ 35
5.1.4 Concluding remarks and future perspectives ...................... 38
5.2 The role of HMGB1 in UVR-induced CLE .................................... 38
5.2.1 Rationale, aims and methodological approach.................... 38
5.2.2 Results .................................................................................. 39
5.2.3 Discussion ............................................................................ 42
 
5.2.4 Conclusion............................................................................44
5.3 Ro52 in LE........................................................................................44
5.3.1 Rationale, aims and methodological approach....................44
5.3.2 Results...................................................................................45
5.3.3 Discussion.............................................................................46
5.3.4 Conclusion............................................................................48
5.4 NO modulates the cellular localization of Ro52..............................49
5.4.1 Rationale and aims ...............................................................49
5.4.2 Results...................................................................................50
5.4.3 Discussion.............................................................................51
5.4.4 Conclusion............................................................................52
6 A hypothesis on CLE/LE pathogenesis .....................................................53
7 Concluding remarks ...................................................................................58
8 Acknowledgements ....................................................................................60
9 References...................................................................................................63
 
 
 
 
 LIST OF ABBREVIATIONS 
 
  
  
Ab Antibody 
ACLE Acute cutaneous lupus erythematosus 
ACR American College of Rheumatology 
AE Adverse event 
ANA Antinuclear antibodies 
APC Antigen presenting cell 
AR Antigen retrieval 
BCR B cell receptor 
C Complement component 
CCLE Chronic cutaneous lupus erythematosus 
CLE Cutaneous lupus erythematosus 
CTL Cytotoxic T lymphocyte 
DC Dendritic cell 
DEJ Dermo-epidermal junction 
ds Double stranded 
dsDNA Double stranded DNA 
EBV Epstein Barr virus 
HMGB1 High-mobility group box 1 
IC Immune-complex 
ICAM Intercellular adhesion molecule 
ICLE Intermittent lupus erythematosus 
IFN Interferon 
Ig Immunoglubulin 
IHC Immunohistochemistry 
IL Interleukin 
iNOS Inducible nitric oxide synthase 
IRF Interferon regulatory factor 
LBT Lupus band test 
LE Lupus erythematosus 
 
LET Lupus erythematosus tumidus 
LPS Lipopolysaccharide  
mAbs Monoclonal antibodies 
MED Minimal erythema dose 
MHC Major histocompatibility complex 
MTD Minimal tanning dose 
NK Natural killer cell 
NLE Neonatal lupus erythematosus 
NO Nitric oxide 
PAMP Patogen associated molecular pattern 
PBMC Peripheral blood mononuclear cell 
pDC Plasmacytoid dendritic cell 
qPCR Quantitative polymerase chain reaction 
RAGE Receptor for advanced glycation end products 
ROS Reactive oxygen and nitrogen species 
SCLE Subacute cutaneous lupus erythematosus 
SLE Systemic lupus erythematosus 
SS Sjogren’s syndrome 
ss Single stranded 
TCR T cell receptor 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TRIM Tripartite motif 
UVA Ultraviolet A radiation 
UVB Ultraviolet B radiation 
UVR Ultraviolet radiation 
 
    
   1 
1 BACKGROUND 
  
1.1 LUPUS ERYTHEMATOSUS 
 
The term Lupus Erythematosus  (LE) (in Latin – the red wolf) dates from 19th century 
when the French physician Cazenave described the facial changes resembling a wolf 
bite in their appearance [1]. Interestingely, already in the first descriptions of LE it was 
emphasized that weather factors could aggravate the disease.  
 
Lupus erythematosus (LE) is a prototype systemic autoimmune disease in which the 
immune system is directed to ubiquitous intracellular molecules:  nucleic acids and 
cellular proteins. LE has a range of clinical manifestations with varying severity and 
prognosis. LE can manifest solely as a dermatological disease and is then denoted 
cutaneous LE (CLE). Systemic LE (SLE) commonly involves skin, joints, the 
cardiovascular system, the CNS, serous cavities and is a potentially life-threatening 
disease. In a temporal perspective, demarcation between the limited cutaneous or life-
threatening SLE is not completely clear as localized disease can progress into systemic 
disorder or systemic condition may remit. The hallmark of SLE is presence of 
autoantibodies against intracellular targets. Antinuclear autoantibodies (ANA) and anti-
double stranded DNA antibodies (anti-dsDNA) are the most specific for SLE [2]. Anti-
Ro/SSA autoantibodies is the third most common variety detected in SLE patients [3]. 
Not all patients carrying these autoantibodies necessarily fulfill the ACR criteria for 
SLE. Anti-Ro/SSA positivity is prevalent among photosensitive patients who have 
CLE diagnosis [4, 5].  
 
Extensive clinical diversity in the disease symptoms emphasizes the challenge to the 
physician in establishing diagnosis and evaluating prognosis. These rely on the overall 
clinical picture together with laboratory and serological findings, possibly including 
skin or renal biopsies. In order to categorize the symptoms and objective findings into a 
diagnosis, the American College of Rheumatology (ACR) proposed SLE classification 
criteria in 1982 [6]. The latest update of the original criteria was proposed in 1997 
(Table 1) [7].  
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Table 1  
The Revised ACR Classification Criteria for Systemic Lupus Erythematosus  
(Abbreviated from Tan et al [6] with the update by Hochberg [7] ).-
______________________________________________________________________ 
Criterion   Definition 
1 Malar rash  Fixed erythema, flat or raised, over the malar  
   eminences, tending to spare nasolabial folds  
 
2 Discoid rash  Erythematous raised patches with adherent 
   keratotic scalling and follicular plugging;  
   atrophic scarring may occur in older lesions 
 
3 Photosensitivity Skin rash as a result of unusual reaction to  
   sunlight by patient history or a physician’s 
   observation 
 
4 Oral ulcers  Oral or nasopharyngeal ulceration, usually 
   painless, observed by a physician 
 
5 Arthritis  Non-erosive arthritis involving 2 or more  
   peripheral joints  
 
6 Serositis  a) pleuritis or b) pericarditis 
 
7 Renal disorder Persistent proteinuria >0.5 g/24h or cellular  
   casts 
 
8 Neurologic disorder a) seizures or b) psychosis 
 
9 Hematological disorder a) hemolytic anemia with reticulocytosis or 
b) leukopenia or c) lymphopenia or d) 
thrombocytopenia 
 
10 Immunological disorder a) anti-dsDNA or b) anti-Sm or  
c) positive finding of phospholipid antibodies 
or d) false positive test for syphilis 
 
11 Antinuclear antibodies An abnormal titer of antinuclear antibodies by 
immunofluorescence or an equivalent assay at  
any point in time and in the absence of drugs  
known to be associated with the “drug-
induced lupus “ syndrome 
  
 
The presence of four or more of the total 11 criteria is necessary for the diagnosis of 
SLE. The criteria provide high sensitivity (96%) and specificity (92%) for the diagnosis 
[6]. In clinical practice it is usually patients that have already developed moderate or 
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severe disease manifestations that fulfill the requirement of four criteria. For patients in 
the initial phase of SLE or with mild manifestations these criteria are less sensitive and 
it is up to each specialist to be alert and to not miss a diagnosis or discontinue follow-up 
[8, 9].    
Notably, mucocutaneous involvement comprises a substantial part of the diagnostic 
criteria for SLE (4 out of 11), and the data from the SLE cohort at Karolinska 
University Hospital indicate that up to 87% of SLE patients have cutaneous 
manifestations [10].  
 
1.1.1 Photosensitivity in LE 
 
Already in the very first descriptions by Cazenave sun exposure has been associated 
with lupus erythematosus skin lesions [1]. Freund followed 507 LE patients during 
1920-1927 and observed clustering of inductions and exacerbations of the disease 
within the spring and summer months. During the period when phototherapy was being 
introduced into dermatology, a few cases of patients with DLE who were treated with 
UV lamps were reported to develop systemic manifestations (reviewed by Lehman 
[11]). Case reports of SLE induced in previously healthy individuals following 
extensive sun exposure have also been described [12, 13]. CLE lesions have a 
predilection to appear in a photo-distributed pattern and are commonly localized to the 
head, décolleté, neck, upper back, extensor aspects of the arms and forearms and dorsal 
aspects of the hands [14-16]. It thus appears that in a susceptible individual sun 
exposure can induce exacerbation of LE, but importantly even systemic disease in a 
previously healthy individual.  
 
Photosensitivity is commonly reported by LE patients and serves as one of the eleven 
ACR criteria for the diagnosis of SLE (table 1). The ACR definition for 
photosensitivity is relatively difficult to interpret in several aspects. Sun-induced CLE 
lesions typically develop with a certain delay of several days up to several weeks and 
therefore the patient may miss to relate and admit sun exposure. In addition, another 
photodermatosis, polymorphic light eruption, is common among CLE patients, and 
when described by a patient and not examined by a specialist could easily be confused 
with and regarded as being sun sensitivity [17, 18]. Several experts have criticized the 
ACR definition of photosensitivity and a more objective definition of photosensitivity 
is of interest [19]. 
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1.1.2 Autoantibodies in LE 
 
The ACR classification criteria for SLE include the presence of antinuclear (ANA) 
and/or anti-RNP and/or anti-Sm and anti-dsDNA autoantibodies [6]. Anti-dsDNA 
autoantibodies are highly specific for SLE and are detected in approximately 70% of 
patients, but in less than 0.5% of the healthy population or patients with other 
autoimmune diseases [20]. The spectrum of LE-associated antibodies is much broader 
than that included in the ACR classification criteria for SLE. Many of the targeted 
molecules are ubiquitous cellular proteins, but autoantibodies against cell surface and 
soluble molecules can also be identified in some patients [21]. In addition to the above 
mentioned specificities, other detectable varieties include anti-La/SSB, rheumatoid 
factor, anticardiolipin, anti-ȕGP1, anti-CRP and anti-HMGB1 [3, 22, 23].      
 
Autoantibodies against Ro/SSA characterize a subgroup of lupus patients who have 
CLE, a history of photosensitivity and an increased risk for development of a neonatal 
lupus syndrome (NLE) in the fetus during pregnancy [15, 17, 24, 25]. About 30% - 
60% of all SLE patients have anti-Ro/SSA autoantibodies [4, 10]. Those diagnosed 
with purely CLE exhibit anti-Ro/SSA in the following frequencies: 83% of SCLE and 
26% of DLE patients [4, 15, 17]. In addition, these autoantibodies are associated with 
primary Sjögrens syndrome (SS) and dermatomyositis with anti-synthetase syndrome 
[2, 26]. It was reported that up to 0.2-0.44 % of healthy blood donors test positive for 
anti-Ro/SSA [27, 28]. Probably some of these individuals will progress into an 
autoimmune disease in the future, since anti-Ro/SSA autoantibodies are reported to be 
detected several years before the development of a systemic disease [9]. Notably, two 
sub-specificities under the common title Ro/SSA have been identified and are directed 
against autoantigens Ro52 and Ro60 [29]. CLE patients usually have higher levels of 
anti-Ro52 than anti-Ro60 [24]. In the literature many authors do not specify the two 
autoantibody specificities in more detail due to historical tradition and there is still no 
clear consensus among scientists and clinical practitioners if it is correct to do so. It 
seems that separate testing for both subspecificities is of major importance in the 
obstetric patients and [24, 30]. 
 
Why and how autoantibodies develop against certain intracellular molecules is still 
unknown. Whether the presence of autoantibodies in LE patients is an incidental 
finding or if they are indeed pathogenic and can impede the function of their 
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intracellular targets is a question to be answered in the future. NLE is the condition in 
which it is believed that autoantibodies of the IgG type that are transported through the 
placenta to the fetus and directly account for the disease manifestations [25]. 
 
1.2 LUPUS ERYTHEMATOSUS AND THE SKIN 
 
The ACR classification criteria for SLE include only some of all possible cutaneous 
manifestations associated with LE. Skin involvement in LE is classified into two major 
groups according to the observed histopathology of a skin biopsy: LE-specific and LE 
non-specific disease. LE-specific disease is denoted cutaneous LE (CLE) and is further 
sub-classified into several categories which share several common histopathological 
patterns. The initial classification of CLE was suggested by Gilliam in 1977 and a 
modification was proposed by Kuhn in 2003, table 2 [31, 32].  
 
Table 2 
Classification of Cutaneous Lupus Erythematosus (2003) 
Acute cutaneous lupus erythematosus (ACLE) 
 
Subacute cutaneous lupus erythematosus (SCLE) 
 
Chronic cutaneous lupus erythematosus (CCLE) 
 Discoid lupus erythematosus (DLE) 
 Lupus erythematosus profundus (LEP) 
 Childblain lupus erythematosus (CHLE) 
 
Intermittent cutaneous lupus erythematosus (CLE) 
 Lupus erythematosus tumidus (LET) 
 
A diagnosis of CLE is a constellation of anamnestic, clinical, histological and 
serological findings. ACLE, SCLE and chronic CCLE can be present in a patient with 
SLE [32]. ICLE seems to be a purely dermatological disease [31].  
 
LE non-specific cutaneous manifestations include dermatological disorders, but also 
systemic manifestations of life-threatening disease, for example vasculitis.  An 
overview of the variety of LE-nonspecific cutaneous manifestations is presented in 
table 3 [14, 19]. Occurrence of the skin lesions might reflect an underlying clinical 
activity or precede a flare of SLE [11].  
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Table 3 
An overview of LE-nonspecific cutaneous manifestations [14] 
Vascular manifestations: 
Vasculitis 
  Palpable or unpalpable purpura 
  Urticaria-like vasculitis 
  Hypocomplementemic urticarial vasculitis 
 
Livedo reticularis 
 
Raynaud’s phenomenon 
 
Cutaneous ulcers 
 
Palmar erythema  
 
Other manifestations: 
Alopecia 
  Scarring and non-scarring 
- patchy or diffuse 
Oral ulcers 
 
Photosensitivity 
  - restricted to cutaneous symptoms  
- systemic symptoms, e.g. weakness, arthralgia, fever 
Others 
 
The studies included in this thesis were focused on CLE and the following discussion 
will be dedicated to this subject, excluding LE-nonspecific cutaneous manifestations. 
Samples which were investigated in the studies studies included in this thesis originated 
from patients diagnosed ACLE (SLE), SCLE and DLE (the most common variant of 
CCLE). In the following discussion we will therefore concentrate on these subtypes of 
CLE.  
 
1.2.1 Clinical manifestations and prognosis of CLE subtypes  
 
ACLE 
 
ACLE is a CLE manifestation exclusively associated with SLE. The most typical 
appearance of the lesion is a facial erythema of ‘butterfly’ shape over malar eminences. 
Sometimes ACLE can be disseminated as a maculopapular eruption and usually heals 
without scarring [4, 11]. These lesions are often associated with previous sun exposure, 
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and might be mistaken by a patient to be a sunburn [2, 11]. Sun sensitivity is a common 
problem in these patients and is included in the ACR classification for SLE [6]. ACLE 
lesions can last from a few days up to a few weeks and often precede a multisystem 
disease by weeks or months [4, 11].  
 
SCLE 
 
SCLE usually manifests as annular or papulosquamous, psoriasis-like scaling 
erythematous plaques. Lesions usually heal without scarring but may leave hyper- 
and/or hypopigmentation. SCLE is associated with photosensitivity and presence of 
anti-Ro/SSA [15]. Patients often have a mild systemic disease activity manifesting in 
parallel to the development of cutaneous symptoms [16]. Systemic symptoms may 
include musculoskeletal complains, increased erythrocyte sedimentation rate (ESR), 
lymphopenia, anemia, leukopenia and low serum levels of complement factors 2 or 4 
[4, 33]. SCLE can overlap with DLE or ACLE [11]. Severe CNS, progressive kidney 
disease or severe systemic vasculitis are all uncommon in association with SCLE, 
occurring in less than 10% of patients.  
 
CCLE 
 
CCLE includes several sub-variants (Table 2). DLE is the most classical and prevalent 
(98% of all CCLE cases) morphologic lesion in CCLE [5, 16]. DLE lesions are flat or 
slightly elevated, sharply demarcated, scaling erythematous macules or plaques. The 
scale usually extends into dilated follicles. Lesions usually remind coins or disks in 
shape and with time can grow, become confluent and disfiguring. The periphery of the 
plaque is often hyperpigmented secondary to inflammation. After a certain time, lesions 
become depressed with scarring, depigmentation and telangiectasia [11, 16]. DLE 
commonly localizes to the ears, scalp or face and may involve mucosa. DLE localized 
to the neck and above is subcategorized into localized DLE and spread below the neck 
is denoted generalized DLE. DLE lesions localized to the scalp may leave scarring 
alopecia [11]. The presence of DLE serves as one of the ACR criteria for classification 
of SLE [6]. Patients diagnosed with generalized DLE have a higher risk to progress into 
systemic disease and up to 20% of these patients will subsequently develop SLE. 
Progression of localized DLE to SLE is less common [14]. Some of DLE patients have 
also positive serology for anti-Ro/SSA autoantibodies [4, 11]. In DLE patients elevated 
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ESR and hematological abnormalities are observed at a lower frequency than in SCLE 
[4, 5].  
 
1.2.2 Histo- and immunopathology of CLE  
 
Histopathological findings of LE-specific lesions share a pattern of lichenoid tissue 
reaction [32]. The changes include atrophy of epidermis, hydropic degeneration of 
basal cell layer with presence of apoptotic keratinocytes, hyperkeratosis, follicular 
plugging, basement membrane thickening, dermal mononuclear cell infiltrate and 
dermal edema [14]. ACLE, SCLE and DLE subtypes share these histological findings, 
but some of them are more typical and pronounced than others [14, 32]. Differences in 
the opinions exist as to whether ACLE, SCLE and DLE lesions can be reliably 
distinguished by the histopathological appearances alone. Moreover, a similar picture 
of lichenoid tissue reaction/interface dermatitis is observed in dermatomyositis, lichen 
planus lesions and some immune reactions against drugs and viruses (reviewed in [34, 
35]).  
 
As the most common manifestation of ACLE is ‘butterfly rash’ involving the face and 
clinical diagnosis is relatively easy, skin biopsies are therefore seldom acquired for 
diagnostic purposes. Furthermore histopathological changes observed in ACLE, 
especially in the early lesions, are relatively modest and non-specific despite dramatic 
clinical manifestations. Well-established lesions have slightly more prominent changes 
that include a mild degree of vacuolar alteration in the basal keratinocytes, some 
extravasated erythrocytes, cell-poor interface dermatitis and a sparse perivascular 
infiltrate of mononuclear cells, accompanied with some neutrophils. Depositions of 
mucin are usually observed in the dermis. Basal membrane thickening, follicular 
plugging or alteration of epidermal thickness is uncommon [35]. 
 
SCLE usually presents with interface dermatitis with vacuolar degeneration of basal 
keratinocytes and the epidermis is usually atrophic with mild hyperkeratosis. Typical 
findings in the dermis include edema, mucin deposition, a sparse lymphocytic infiltrate 
in the upper dermis (interface), around blood vessels and periadnexal structures [35].  
 
Classical DLE presents with hyperkeratosis, variable epidermal atrophy and/or 
parakeratosis and follicular plugging.  Large numbers of lymphocytes invade the basal 
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epidermis and the follicular epithelium, where basal hydropic degeneration is evident. 
The epidermal basal membrane is markedly thickened. In the dermis dense, patchy, 
perivascular and perifollicular lymphocytic inflammatory infiltrates are accompanied 
by dermal mucin deposition. In the scarring DLE lesions the dense inflammatory cell 
infiltrate subsides and is replaced by dermal fibroplasia [35]. 
 
Immune complexes (ICs) deposited along the dermo-epidermal (DEJ) junction is a 
frequent finding in CLE patients and is detected by direct immunofluorescence [36]. 
This finding is denoted ‘lupus band test’ (LBT). Immunoglubulins (Ig) of IgM, IgG and 
complement components (C), particularly C3, are found most commonly. Positive LBT 
is found in CLE lesions in over 90% of cases. In SLE patients, a positive LBT can be 
detected in uninvolved sun-protected skin and was suggested to be specific for the 
condition [37]. 
 
1.3 GENETIC ASSOCIATIONS IN LUPUS ERYTHEMATOSUS 
 
LE/SLE may cluster to certain families and the estimated concordance rate for lupus is 
24-58% among monozygotic twins and approximately 2-5% in dizygotic twins [38]. 
Sequencing of the human genome and technological advances in genotyping tools has 
led to a revolution in the field of clinical genetics [39]. Genome-wide association 
studies assessing copy number variation and single nucleotide polymorphisms have 
revealed important genetic associations in LE/SLE (table 4). Data indicate that 
predisposition for LE/SLE is inherited in a complex polygenic manner [40]. Many of 
the associated loci encode molecules involved in the innate and adaptive immunity 
[41]. A list of LE/SLE-associated candidate genes and the major putative function 
affected by these is presented in the table 4. 
 
1.3.1 Genetics of CLE and anti-Ro/SSA positive disease 
 
Several studies have reported genetic variations specifically associated with CLE. [14, 
42-44]. The reported candidate genes can be sub-classified into MHC and non-MHC 
genes. The associations observed within the MHC group embody variations in HLA-
DRB*0301, HLA-DRB1*1501, HLA-DRB1*1302, HLA-DRB1*1601, HLDQA*010, 
and also C2, C4, or combined C2 and C4 complement deficiencies. The associations 
observed in non-MHC loci are TNF-Į (-308A), TYK2, IRF5, ITGAM and TREX1. 
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Polymorphisms in the intron 1 and 3 of the Ro52 gene have been associated with and 
anti-Ro52-positive Sjögren’s syndrome and a polymorphism upstream exon 2 has been 
associated with SLE [45-47].  
 
Table 4 
LE/SLE risk loci and associated biological pathways [40, 41, 44, 48, 49] 
Function   Gene 
Adaptive immunity 
 
Antigen presentation  HLA-DR2 (DRB1*0301) 
HLA-DR3 (DRB1*1501)  
 
T and B cell signaling  PTPN22, CTLA4, PDHX/CD44 
BANK1, BLK 
 
T helper cell regulation  STAT4, TNFSF4 
 
Innate immunity 
 
Interferon and TLR7/9 signaling IRF5, TNFAIP3, IRAK1, MECP2, UBE2L3, 
   IRF7, PHRF1, TYK2, IL8, IKBKE  
 
Fc receptor    FCGR2A, FCGR3B 
 
Phagocyte activity  ITGAM 
 
Clearance of immune complex  C1q, C2, C4, CRP   
 
Other    IL-10, TREX1 
 
 
1.4 LE TRIGGERING FACTORS 
 
It was suggested that genetic factors influence an individual’s lifetime risk to develop 
LE and environmental factors are likely to provide a trigger for the onset of clinical 
manifestation(s) of disease [41]. This fact emphasizes the importance of gene-
environment interaction in the induction of LE. 
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1.4.1 The sun and ultraviolet radiation (UVR)  
 
Photosensitivity is a common feature of LE and understanding of the mechanisms 
underlying UV damage to human skin can therefore help in delineating pathological 
processes occurring in LE patients subsequent to the sun exposure.  
 
Sun light 
 
The electromagnetic radiation emitted by the sun that reaches the surface of the earth 
consists of infrared radiation, visible light and ultraviolet radiation (UVR). The visual 
and infrared radiation is important for every living organism on earth, providing light 
and warmth.  The UVR spectrum is less beneficial. UV radiation is responsible for 
activation of vitamin D3, but also accounts for sun-induced skin aging, modulation of 
the immune system and photocarcinogenesis. UVR has the wavelength between 280 
and 400 nm. UV radiation is sub-classified according to the wavelength into UVB (280 
– 315 nm) and UVA (315-400 nm). More UVA reaches the surface of the earth than 
UVB. UVB has a shorter wavelength than UVA, but higher energy and it is therefore 
UVB that leads to sun-burn after a longer exposure outdoors on a sunny day [50]. Due 
to its longer wavelength UVA penetrates through the epidermis to the reticular dermis 
and mediates its effects at this depth, but the effects are relatively modest. Meanwhile 
UVB is more potent but does not penetrate that deeply into the dermis. UVB mainly 
affects the epidermis and papillary dermis (figure 1) [50]. Humans are exposed to 
different amounts of UVR depending upon the latitude they live at. The race-associated 
differences in the natural skin pigmentation are an important factor determining skin 
sensibility to the sun [35]. 
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Figure 1. Penetrating abilities of UVA and UVB [50]. 
 
Immunological consequences of UVR 
 
The sunlight can both suppress and activate the immune system of the human skin [50, 
51]. A longer exposure to intensive sun induces sunburn, i.e. skin inflammation, while 
chronic or minimally erythematogenic doses have predominantly immunosuppressive 
effect [50]. Exposure to UVR induces DNA damage in keratinocytes. The cells are 
usually allowed to repair the damage. However, if the damage is too extensive or repair 
mechanisms fail, such cells undergo apoptosis and are consequently apparent in the 
skin biopsy as apoptotic ‘sunburn’ cells [52]. It is assumed that UVR-induced 
immunosuppression is biologically mediated by DNA damage and keratinocyte-
secreted cytokine IL-10 and that it also depends on UVR-induced depletion of 
Langerhans cells and generation of regulatory T cells [53, 54]. The immunosuppressive 
effect is exploited in phototherapy of dermatological diseases such as psoriasis and 
atopic dermatitis, but may also lead to the development of dermatological neoplasms 
[55].  Proinflammatory effects of UVR are mediated by several mechanisms. 
Keratinocyte exposure to UVR results in increased expression of MyD88, activation of 
Nuclear Factor kappa B (NFkB) and inflammasome, subsequently leading to cytokine 
production and secretion (TNF-Į , IL-1 (Į and ȕ), IL-6,  IL-8 and IL-12). The secreted 
cytokines mediate multiple effects on the adjacent keratinocytes and cells in the dermis 
[50, 56]. The proinflammatory environment induces upregulation of adhesion 
molecules (ICAM1and E-selectin) in the adjacent blood vessels and keratinocytes and 
attracts leukocytes [57]. Production of NO is also induced and may contribute to 
keratinocyte apoptosis and other features of inflammation  [58]. The recruited cells are 
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dedicated to clear the apoptotic keratinocytes and terminate the inflammation (reviewed 
by Maverakis et al.[50]). 
 
Features of UVR-induced cutaneous inflammation in LE patients 
 
Investigations including longitudinal skin biopsy material from experimentally UVR 
induced developing lesions have provided some insights into the biological processes 
occurring in the skin of CLE patients after UVR injury. It was demonstrated that CLE 
patients accumulate increasing numbers of apoptotic keratinocytes in their epidermis up 
to 72 h post-UVR exposure, whereas in healthy controls the increase of apoptotic cells 
is observed 24 h after UVR injury and unviable cells are completely cleared within 72 h 
[59]. It is assumed that accumulation of unviable cells is associated with clearance 
deficiencies and unremoved cells undergo secondary necrosis [60]. The released cell 
debris become opsonized by immunoglobulins and complement components as 
observed a few days later by positive ‘lupus band’ test [36, 61]. Prolonged and delayed 
induction of NO generation, as detected indirectly by the iNOS expression pattern, may 
contribute to an increased amount of apoptotic cells, but also enhance the secretion of 
proinflammatory cytokines and influx of leukocytes [50, 58, 62]. Expression of IFN-
inducible protein MxA has been demonstrated to increase in parallel to the 
development of UVR-induced cellular infiltrates [63], and might therefore be related to 
the induction of IFNȜ1 production by keratinocytes, as observed in spontaneous CLE 
lesions [64].  
 
Several investigators attempted to explore if UVR could modulate the subcellular 
localization of Ro52 and Ro60 in human keratinocytes as anti-Ro/SSA autoantibodies 
are associated with photosensitivity. They demonstrated that Ro52, in parallel to Ro60, 
may translocate to apoptotic blebs after the cell exposure to UVR [65-68].  
 
1.4.2 Smoking 
 
Smoking is clearly associated with several autoimmune diseases: rheumatoid arthritis, 
pustulosis palmoplantaris and psoriasis [4, 69-71]. Smoking is also a risk factor for 
cutaneous manifestations of LE [4, 69, 70, 72], particularly in those with deficiency of 
complement factors C1q, C2, C4 or their combination [33]. Smokers usually have 
lower anti-Ro/SSA autoantibody levels [24]. CLE patients who smoke have less good 
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response to anti-malarial treatment, but cessation of smoking may re-establish 
sensitivity to anti-malarials [33, 73].  
 
1.4.3 Gender and sex hormones 
 
Nine out of 10 SLE patients are women, who usually are in their reproductive age at the 
onset of the disease. Among CLE patients the proportion of female patients varies 62-
76% among CCLE and 69-89% among SCLE patients [4, 5]. Pregnancy can induce a 
flare of SLE [2].  Administration of exogenous estradiol can accelerate and exacerbate 
disease in several lupus-susceptible mouse models [74]. 
 
1.4.4 Viral infection 
 
Several viral infections have been implicated in SLE induction, namely Epstein-Barr 
virus (EBV), parvovirus B19 and retroviruses [2, 75, 76]. This hypothesis might appear 
attractive as type I IFNs mediate antiviral response and ‘interferon signature’ is 
observed in a substantial proportion of SLE patients [77, 78]. It was described that one 
of the EBV proteins interacts with the LE-associated autoantigen La/SSB. This 
observation led to a hypothesis that the adaptive immune system might recognize a 
complex of viral particles and self-protein as a one antigen and thereby initiate 
autoimmunity. In addition, molecular mimicry between the autoantigen Ro60 and EBV 
viral proteins has been suggested (reviewed by James [75]). There is little evidence that 
viruses can directly induce LE. A possibility exists, that virus induced immune system 
activation may trigger LE in a genetically susceptible individual [79]. Importantly, 
symptoms of several viral infections may imitate SLE [2]. It is therefore 
recommendable to screen patients with SLE-like symptoms, for presence of certain 
viral infections [2].  
 
1.4.5 Drugs  
 
Several drugs have been associated with SLE and CLE induction. Treatment of viral 
infections with IFNĮ is associated with a risk of triggering SLE [80]. Development of 
cutaneous LE lesions at the site of imiquimod application (which is a TLR7 agonist and 
induces IFNĮ production by pDCs) has been reported [81, 82]. Interestingly, other 
classes of drugs that have been reported to induce SCLE lesions have little overlap with 
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those associated with drug-induced SLE (reviewed by Sontheimer in [83]).  The list of 
SCLE-inducing drugs include calcium channel blockers, thiazide diuretics, antifungals, 
angiotensin converting enzyme inhibitors, ȕ-blockers and proton pump inhibitors [8, 
83]. Drug induced-SCLE cases are Ro/SSA positive at a similar rate as the idiopathic 
ones. It might be the case that a proportion of patients with drug-induced CLE had 
already had autoantibodies before the exposure to the medication, but the drug 
administration led to a clinical manifestation of the disease [8]. In contrast to the drug-
induced SLE, positivity for anti-histone antibodies is detected only in less than half of 
drug-induced SCLE cases. Skin lesions usually resolve upon drug discontinuation, but 
not the anti-Ro/SSA autoantibodies [83].  
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2 AUTOIMMUNE INFLAMMATION IN THE TARGET 
ORGAN  
 
Components of the innate and adaptive immune systems are involved in the disease 
processes of LE and those that are thought to be of major importance according to the 
currently available data will be overviewed below.  
 
The skin damage observed in a histopathological picture of CLE is mediated by the 
autoreactive immune system. It is thought that the cascade of events leading to LE is 
usually initiated by an external factor that has cell-death inducing and/or 
proinflammatory nature (e.g. UVR, drugs). The observed changes in the CLE lesions 
include many signs of ongoing inflammation (figure 2) [14]. Apoptotic cells are 
present in the basal and the adjacent layers of epidermis [59]. Deposits of ICs are 
displayed at DEJ and some of them probably include cell debris opsonized by 
immunoglobulins and complement components, as detected by a positive ‘lupus band’ 
test in the majority of CLE lesions [14, 36]. Proinflammatory cytokines such as 
HMGB1, TNF, IL-1, IFNȜ, IL-17 and IL-18 are expressed in the CLE lesions [64, 84-
86]. They may further induce upregulation of chemokines and adhesion molecules at 
the site of injury. The upregulated adhesion molecules observed in the involved skin 
include ICAM1 and E-selectin and facilitate leukocyte influx [57, 63]. The Th1 type 
chemokines (CXCL9, CXCL10, CXCL11 and CXCL12) are the most strongly 
upregulated out of the whole chemokine family and are observed in those areas where 
epidermal and dermal injury is evident [87-90]. These chemokines may home 
lymphocytes bearing their ligands CXCR3 and CXCR4 and cells positive for these 
markers are detected within the lesions [89, 90]. Presence of CXCR4 expressing cells 
suggests accumulation of cutaneous DCs [91]. A substantial portion of the infiltrating 
cells are cytotoxic CD8+ and effector CD4+ T lymphocytes that might have been 
recruited via CXCR3 [34, 88]. Macrophages (CD68+ cells) and pDCs are also present 
among dermis infiltrating cells [90, 92]. Notably, upregulation of IFN-inducible genes 
is evident in CLE lesions and includes IRF5, IRF7, MxA, CXCL9, CXCL10 and 
CXCL11 [42, 63, 89]. Evidently, keratinocytes seem to be poor producers of type I or 
II IFNs, but it has been recently demonstrated that they can produce IFNȜ1 and express 
its receptor. Upregulation of this cytokine and its receptor in CLE lesions has been 
recently reported [64]. 
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To conclude, the available knowledge suggests that CLE is driven by a Th1 immune 
response in parallel to the activated IFNs system. B cells secreting a special profile of 
autoantibodies are also typical for the condition.  
 
 
Figure 2. Histopathology of CLE lesion demonstrates inflammation.   
 
The components of the immune system that are of specific interest in this thesis will be 
discussed in more detail below. 
 
2.1 HMGB1  
 
High mobility group box chromosomal protein 1 (HMGB1) or previously denoted 
amphoterin, is present in the nucleus of all nucleated cells and was known for many 
years as a protein with important nuclear functions [93]. HMGB1 contains two DNA-
binding domains denoted box A and box B and is involved in transcription, replication 
and DNA repair [94, 95]. A decade ago novel qualities of extracellular HMGB1 were 
discovered. It was demonstrated that HMGB1 plays important roles in inflammation, 
regeneration and tumor-genesis [95-98].  The B box mediates the proinflammatory 
cytokine functions of the molecule, whereas the A box has an antagonistic anti-
inflammatory effect [99]. HMGB1 can be passively released from the necrotic cells and 
alerts the body about injury [95]. It can also be actively secreted by activated cells by a 
non-classical pathway via secretory HMGB1-containing lysosomes [100].  
 
 
 18 
2.1.1 HMGB1 in inflammation  
 
Several types of leukocytes, such as monocytes, macrophages and dendritic cells, can 
be induced to actively secrete HMGB1. This usually occurs upon sensing conserved 
molecular motifs expressed on microbes (PAMPs, like lipopolysaccharide (LPS)) 
and/or pro-inflammatory cytokines (TNF-Į, IL-1ȕ and IFN-Ȗ) [101]. The secreted 
HMGB1 functions as an alarmin with proinflammatory cytokine-like properties and 
enhances the immune response of the host. Extracellular HMGB1 can stimulate the 
surrounding cells inducing cytokine secretion via activation of NFțB, chemokine and 
adhesion molecule expression, as well as generation of ROS in the phagocytes [95, 
102-104]. HMGB1, via interaction with CXCL12, guides chemotaxis of DCs and 
macrophages [105]. In addition, this protein is also important for maturation and 
activation of pDCs and T cells [106, 107]. HMGB1 functions via several receptors 
including RAGE, TLR2, TLR4 and TLR9 [99]. HMGB1 can act in solo or build 
complexes with other endogenous (IL-1ȕ) and exogenous (LPS, nucleic acids) 
molecules to amplify its proinflammatory effect [108, 109].  
HMGB1 is a mediator of both acute and chronic inflammation. High levels of HMGB1 
in peripheral blood are associated with lethality in septic and hemorrhagic shock 
syndromes [110, 111]. The list of chronic inflammatory diseases in which HMGB1 is 
implicated as an important actor is constantly increasing [99, 112]. 
 
2.1.2 HMGB1 in autoimmunity 
 
HMGB1 has been of great interest among immunologists during the last decade due to 
its role in the pathogenesis of inflammatory and autoimmune diseases. HMGB1 is 
detected in synovia and synovial fluid of patients with rheumatoid arthritis and 
HMGB1 blockade or inhibition alleviates the disease in animal models [99, 113]. 
Extracellular HMGB1 is detected in the muscle biopsies of patients diagnosed with 
inflammatory idiopathic myositis [114]. Patients with SLE have circulating HMGB1 
and anti-HMGB1 autoantibodies in the peripheral blood [23, 99]. Intriguingly, HMGB1 
complexed to nucleosomes has been demonstrated to induce IFNĮ production by pDCs 
and initiate autoimmune responses against dsDNA [115-117]. ICs containing HMGB1 
might therefore be important players in the breakage of immunological tolerance to 
self-nucleic acids, a major target of autoantibodies in SLE. Importantly, our group has 
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recently demonstrated that HMGB1 was upregulated and translocated to the 
extracellular space in the spontaneous skin lesions of CLE patients [84]. 
 
2.2 Ro52  
 
The Ro52 protein is one of the autoantibody targets in LE and Sjögrens syndrome 
patients [21, 118]. Ro52 was described in 1988 as one of the proteins targeted by 
Ro/SSA antibodies [29]. Historically, due to inaccuracies associated with 
methodological difficulties, Ro52 was thought to be associated with autoantigenic 
protein Ro60 into a complex denoted Ro/SSA [29]. Later, cloning and characterization 
of the Ro52 molecule allowed definition of the domains building the protein and 
indicated that there was no homology whatsoever with the Ro60 protein [119, 120]. 
Rather, Ro52 contains a RING and a B-box motifs, followed by a coiled-coil (CC) 
domain and a B30.2 (or PRYSPRY) region in the C-terminal end (figure 3) [121]. The 
RING, B-box and CC motif (RBCC) places Ro52 within the tripartite motif protein 
(TRIM) family [122]. Ro52 is thus also denoted TRIM21, and Trim21 is the official 
name of the Ro52 gene [122].  
 
 
 
Figure 3. The structural domains of Ro52.  
 
2.2.1 The functions of Ro52  
 
Like several other TRIM proteins, Ro52 has an E3 ligase activity and acts in the 
process of ubiquitination [123]. Ubiquitination is a mechanism of post-translational 
modification of proteins that allows eukaryotic cells to control biological processes 
such as protein degradation, trafficking and activation [124].  The process of 
ubiquitination is a complex three-step pathway requiring energy (ATP). The first step 
includes binding and activation of ubiquitin molecule by an ubiquitin activating 
enzyme (E1). The activated ubiquitin molecule is then transferred to an ubiquitin 
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conjugating enzyme (E2). In the last step, an ubiquitin ligase (E3) mediates the transfer 
of the ubiquitin to the target protein (figure 4)[125]. It has been demonstrated that Ro52 
can interact with E2s UBE2D1 and UBE2E1 located in the cell cytoplasm and nucleus, 
respectively [123, 126, 127]. Described substrates for Ro52-mediated ubiquitination 
include interferon regulatory factors (IRF) IRF3, IRF5, IRF7 and IRF8 [128-131]. It 
was demonstrated that Ro52 mediates ubiquitination of IRF3, IRF5 and IRF7 and can 
target these transcription factors for degradation.  Dual data was reported regarding 
IRF8 and IRF3 and it seems that Ro52 may sustain their activity in certain cell types 
and conditions and direct them to degradation under other conditions [128, 130, 132].  
 
 
 
Figure 4. Post-translational modification with ubiquitin. A ubiquitin (Ub) molecule is 
activated and bound to the E1 (a), then transferred to the E2 (b) and finally E3 
facilitates its attachment to the substrate (S) (c). Several ubiquitin molecules can be 
attached to the substrate if necessary (d).   
 
It was observed that overexpression of Ro52 in a B cell line results in the increased cell 
sensitivity to the activation induced cell death [123]. In contrast to these findings Sabile 
et al reported that knock-down of Ro52 leads to an impaired progression of the cell 
cycle [133]. These observations are made in in vitro systems using different cells and 
experimental conditions. More investigations are needed to allow a better 
understanding what roles Ro52 has in the regulation of the cell cycle. 
 
Several investigators have reported that Ro52 via its B30.2/PRYSPRY domain can 
bind to the Fc part of any IgG with unexpectedly high affinity, comparable to that of 
bacterial superantigen protein A [134, 135]. So far, it is not clear if this binding occurs 
in vivo.  
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2.2.2 The expression of Ro52  
 
Ro52 is a predominantly cytoplasmic protein expressed in the cells of the immune 
system, as observed in a genetically modified animal [131, 136]. Ro52 becomes 
upregulated in a pro-inflammatory environment, such as exposure to type I and II IFNs 
[134, 137]. Cell stimulation with IFNĮ or H2O2 may lead to the accumulation of Ro52 
in the cell nucleus [68, 137]. UVR has been demonstrated to induce Ro52 translocation 
to apoptotic blebs in keratinocytes and salivary ductal epithelia [66, 138]. 
 
SLE patients have higher numbers of Ro52 transcripts in the peripheral blood 
mononuclear cells (PBMC) as compared to healthy controls, although protein levels do 
not differ substantially [123].  
 
2.2.3  Ro52 and interferon (IFN) responses in LE 
 
A positive test for anti-Ro/SSA autoantibodies (and also ds-DNA) is associated with 
the presence of high IFNĮ activity in SLE patients [139]. Data reported by several 
groups indicate that Ro52 is an IFN-inducible protein and can regulate IFN responses. 
In evolutionary regard, type I IFN system evolved to protect the host against viral 
infections [77] and several members of TRIM protein family are important in the 
regulation of these responses [140].  
 
Interferons (IFNs) and the regulatory role of Ro52  
 
IFNs are subclassified into type I, II and III. Type I IFNs include several subtypes of 
IFNĮs and IFNȕ that are important in the antiviral response [77]. IFNȖ belongs to type 
II IFNs and mediates host defense against intracellular microbes [77]. IFNȜ1 is the 
most important member of type III IFNs and seems to have an important role in the 
antiviral and antitumor response in epithelial cells such as keratinocytes [141]. 
Plasmacytoid dendritic cells (pDCs) are the most potent producers of IFNĮ, but can 
also produce IFNȜ [78, 142]. Transcription of type I IFNs is regulated by IRFs. IRFs 
are usually activated after the cell senses intracellular viral or bacterial nucleic acids via 
TLR-3, -7 or -9 or cytoplasmic sensors RIG1 or MDA5 [77]. IFNĮ has multiple effects 
on the host cells: can induce apoptosis of virus infected cells and stimulate the immune 
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response, including maturation and activation of APCs, activation of Th1 T cells, 
prolonging survival of cytotoxic T cells and enhancing antibody production in B cells 
[143-145]. Data indicate that Ro52 has a regulatory role in IFN responses and is 
involved in a regulatory loop: its expression can be upregulated by type I and II IFNs 
[134, 137] and Ro52 can subsequently inhibit IFNs and their inducible cytokines (IL-
12/IL-23p40, IL-6, and TNF alpha) [130, 131].  
 
IFNs in LE 
 
Notably, a major part of LE patients display presence of ‘IFN signature’, i. e. 
upregulation of IFN-inducible genes is observed in their PBMCs and also CLE lesions 
[78, 89, 90]. A part of SLE patients also have increased IFNĮ concentrations in their 
peripheral blood [48, 78, 89, 90]. Interestingly, it was recently reported that a type III 
IFN (IFNȜ1) and its receptor are highly expressed in CLE lesions and that serum levels 
of IFNȜ1 correlate with the activity of CLE [64].  
 
Genetic associations between LE and molecules involved in different pathways of 
interferon responses have been reported. These include molecules involved in sensing 
intracellular foreign nucleic acids (MDA5) and signal translation via the interferon 
receptor (TYK2). Additionally, polymorphisms in the transcription factors or other 
molecules involved in signal transduction downstream these receptors have also been 
reported (IRF5, IRF7, IRF8, IRAK1 and STAT4) (reviewed in [48]).  
 
2.3 REACTIVE OXYGEN AND NITROGEN SPECIES (ROS) 
 
ROS are a group of highly reactive oxygen derivatives. This group includes several 
gaseous molecules with a simple structure and a short half-life: nitric oxide (NO), 
hydrogen peroxide (H202), peroxynitrite (ONOO). Activated leukocytes can produce 
ROS at the site of inflammation in order to kill invading microorganisms [77]. Skin 
exposure to UVR can induce keratinocytes and dermal endothelial cells to produce and 
release ROS, including NO [146, 147]. NO is an important mediator participating in 
vasodilation, signal transmission, apoptosis and wound healing [58, 148, 149]. It 
appears that the effects mediated by NO are determined by its concentration: low 
concentrations stimulate cell proliferation during wound healing, but high have 
cytostatic and proinflammatory effects [58, 150].  
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NO is a short-lived molecule and is therefore difficult to detect in a living organism. 
The track of NO production can be estimated by determining the presence of nitric 
oxide synthases (NOS) that are responsible for its production in the tissues [147, 150]. 
The synthases generate NO from L-arginine, producing equal amounts of citrulline 
(reviewed in [58]). Keratinocytes constitutively express nNOS (neuronal NOS) and 
dermal endothelial cells express eNOS (endothelial NOS). These enzymes are 
responsible for constant low production of NO and are often denoted by the common 
name constitutive NOS (cNOS). Constant NO production is necessary for maintenance 
of skin barrier function and blood circulation [58]. Inducible NOS (iNOS) is 
synthesized in response to various stimuli, including sun exposure or skin wounding 
[147]. UVR upregulates iNOS expression in the skin and sun-burn induced NO is one 
of the molecules responsible for the inflammatory skin reaction [58, 62].  
 
Increased iNOS expression has been reported in the lupus nephritis kidney and UVR 
induced CLE skin lesions [62, 151]. Generation of NO and its derivate peroxynitrite 
(ONOO) (when NO encounters superoxide molecule) might modify autoantigens and 
form neo-epitopes [152]. It has been demonstrated that DNA modified with ONOO 
was more immunogenic than native DNA in an animal model of LE [153]. 
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3 ASPECTS OF THE SYSTEMIC AUTOIMMUNE 
INFLAMMATION IN LE  
 
3.1 CELL DEATH 
 
Apoptosis is an essential phenomenon needed to ensure cellular homeostasis of 
multicellular organisms. It allows elimination of dangerous, damaged or unnecessary 
cells. This mechanism is highly controlled in order to insure removal of the right cells 
and to reduce the risk of damage to the surrounding tissues [154]. Apoptosis is usually 
a non-inflammatory process mediated by mononuclear phagocytes that secrete anti-
inflammatory cytokines IL-10, TGFȕ, and NO after the engulfment of unviable cells 
[155]. Efficient clearance of apoptotic cells is important to prevent exposure of self- 
antigens to the immune system. Conversely to apoptosis, necrosis is usually caused by 
external signals and subsequently molecules dedicated to alarming about the danger are 
released [95]. They are denoted alarmins and include HMGB1 and other molecules 
[95]. If apoptotic cells are not cleared within an appropriate time limit they undergo 
secondary necrosis and release intracellular constituents to the surrounding extracellular 
space [60]. HMGB1 tightly bound to chromatin is included in the debris released from 
necrotic cells and may elicit immune response against DNA [60, 115].  
It has been demonstrated that lupus patients accumulate increased numbers of dying 
cells in the different tissues, including skin and lymph nodes [59, 156]. It is thought that 
it depends on clearance deficiency and/or on accelerated apoptosis.   
 
3.2 CRP AND ANTI-CRP ANTIBODIES 
 
CRP is an acute phase reactant and belongs to the pentraxin family [77]. It is produced 
by hepatocytes upon stimulation with IL-6 and IL-1. A distinct feature of CRP is a very 
prompt elevation (within first hours) following tissue injury. CRP, together with other 
opsonins such as C1q, IgG, is important in opsonization of the apoptotic cells and 
facilitation of phagocytosis [22, 157, 158]. SLE patients usually have low levels of 
CRP during flares, despite that they can produce large amounts of it upon infections 
[157]. The reason of low CRP levels during SLE exacerbations is not clear, but it was 
suggested that increased production of IFNĮ might have a role [157]. It is possible, that 
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lack of CRP contributes to impaired phagocytosis of apoptotic debris. Paradoxically, 
CRP levels are constantly at the upper level of the normal range in the majority of SLE 
patients. It seems that slight, but constant CRP elevation, is associated with increased 
incidence of cardiovascular disease in SLE patients [22, 157]. Moreover, many SLE 
patients have anti-CRP autoantibodies [22]. Anti-CRP Abs might contribute to LE 
pathogenesis by neutralizing CRP, increasing the numbers of circulating immune 
complexes and by atheroma plaque destabilization [157]. Polymorphism in the human 
CRP locus has been determined in SLE patients and was suggested to possibly 
influence basal CRP expression and as well as predispose to SLE development [158].      
 
3.3 COMPLEMENT 
 
The complement system is an important player in the immune response and, in 
particular, in clearance of apoptotic and necrotic cells [159]. Deficiencies of the 
complement components have been associated with LE, but interestingly, not with any 
other autoimmune disease [33]. 
 
The complement system is involved in elimination of immune complexes (ICs) and 
interaction of its components with CRP is of major importance in this process [158, 
160]. CRP activates the complement cascade and  upregulates complement receptors on 
phagocytes (reviewed in [158]). Low or immeasurable levels of certain complement 
components might be present due to genetic predisposition, impaired regulation of the 
complement system and/or consumption during inflammatory processes. Genetic 
deficiencies of complement components are associated with susceptibility to infectious 
diseases, but also SLE. Notably, SLE patients with total or partial C2, C4 or combined 
C2 and C4 deficiencies usually manifest with CLE lesions, photosensitivity and anti-
Ro/SSA Abs, but seldom test positive for anti-dsDNA [33].  
 
3.4 PHAGOCYTES AND RECOGNITION OF ICs  
 
The phagocytes of the innate immune system include macrophages and monocytes, 
denoted mononuclear phagocytes, and neutrophils, termed polymorphonuclear 
phagocytes [77]. These cells are responsible for the recognition of antigen via pattern 
recognition receptors or FcȖRs (opsonized antigens). Antigen recognition is usually 
associated with its engulfment with the purpose to eliminate it. Phagocytes are recruited 
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to the site of inflammation via chemokine gradient and interactions with cell adhesion 
molecules [77]. The removal of unviable cells and ICs is impaired in a substantial 
proportion of LE patients [60]. The available data indicate that phagocytes have 
reduced abilities to recognize cell debris and ICs most probably due to genetic 
polymorphisms of the genes encoding their receptors, such as complement receptor 
3/integrin-ĮM, FcȖR2A and FcȖRIIIb [41, 161]. 
 
3.5 THE ADAPTIVE IMMUNE SYSTEM IN LE 
 
Multiple abnormalities in the activation and function of the cells of the adaptive 
immune system have been described in LE patients. In particular, it seems that a type 1 
(Th1) CD4+ T cell response with over-activation of pDCs that secrete high amounts of 
IFNĮ and B cells that secret a variety of autoantibodies have major roles in the 
pathogenesis of autoimmunity in LE. During recent years an important role of Th17 
response has been also implicated in LE and these cells seems to have an interplay with 
Th1 cells.    
 
3.5.1 Dendritic cells (DCs) and LE 
 
The conventional DCs (cDCs) are termed professional antigen presenting cells (APCs) 
and their major function is antigen recognition, processing and presentation to T cells. 
Thus cDCs bridge innate and adaptive immunity [77]. It is believed that DCs are 
involved in the presentation of autoantigens to the adaptive immune system in 
autoimmune diseases [77]. It has been demonstrated that ICs containing autoantigens, 
such as HMGB1-nucleosome complexes, induce DC maturation and activation [115]. 
DCs derived from LE patients respond to such stimulation by secretion of much higher 
amounts of IL-12 as compared to the controls [162]. Intriguingly, several reports 
demonstrated that C1q deficiency results in the impaired recognition and engulfment of 
ICs by macrophages and therefore such ICs could be phagocytosed by DCs [163-165]. 
This could increase the chances for autoantigen presentation to T and/or B cells.  
 
Plasmacytoid DCs (pDCs) are specialized for recognition of viral and bacterial nucleic 
acids through their endosomal receptors TLR-3, -7 and -9 or cytoplasmic sensors 
(RIG1 and MDA5). They can also recognize ICs via FcȖRIIa [166, 167]. Activated 
pDCs upregulate the CXCR3 receptor, which directs them to the target tissue 
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expressing its ligands (CXCL-9, -10 and -11) [168, 169]. pDCs are detected in CLE 
skin lesions and are potent producers of type I IFNs [78, 92, 170]. Immune complexes 
can activate pDCs and induce IFNĮ production and C1q was demonstrated to be an 
important signal suppressing this activation [171]. It may be the case that the C1q 
deficiency observed in some of SLE patients is one of the important factors whereby 
IFNĮ production is not terminated in time. 
 
3.5.2 T cells and LE 
 
The available data demonstrate the involvement of Th1 and Th17 effector cells in the 
autoimmunity of LE [172-174]. Increased levels of circulating Th1 profile cytokines, 
IFNȖ, IL-12 and IL-18 have been observed in SLE patients, especially in those with 
involvement of vital organs, such as kidneys [175]. Production of Th1 cytokines occurs 
in LE target organs, including kidneys and skin [85, 176]. In parallel, increased levels 
of circulating CD4+ and CD4-CD8- double negative T cells of Th17 subtype have also 
been reported in SLE patients [177]. IL-17 producing cells were demonstrated in lupus 
nephritis kidney and CLE lesions [86, 172, 178].  
 
It is probable that the adaptive autoimmune response in LE patients is initiated when 
DCs, matured in the proinflammatory environment, take up the autoantigen released 
from secondary necrotic cells (as it is or opsonized) and present it to the naive 
(probably low self-reactive) T cells. Antigen recognition, accompanied by the 
costimulatory signal, usually leads to CD4+ T cell activation and clonal expansion of 
effector T cells. DCs could also activate CD8+ T cytotoxic T (CTLs)  cells via cross-
presentation [77]. Self-reactive Th1 cells might have multiple roles in LE: provide help 
to autoantibody secreting B cells, assist in recruitment of other cells to the site of 
inflammation, enhance the killing properties of phagocytes and CTLs [174]. Presence 
of CD4+ , CD8+  and granzyme B or Tia1 positive cells was demonstrated in the CLE 
lesions [90]. 
 
Importantly, pDCs may divert the differentiation of CD4+ cells to the Th17 phenotype 
in the presence of nucleic acids containing ICs in vitro [179]. Activated T cells of Th17 
phenotype might contribute to the injury of the target organ by attracting and activating 
neutrophils. Th17 cells can stimulate B cells to produce more autoantibodies that will 
form immune-complexes with the cell constituents released from the dead cells and 
 28 
may thus amplify the vicious proinflammatory circle [172]. Th17 axis seems to be of 
major importance in an animal model of lupus-like disease that develops in a 
genetically modified mouse lacking Ro52. Disruption of the Th17 pathway provided a 
complete protection from systemic autoimmunity, otherwise developing after minor 
skin injury in this model [131].   
 
The immune system has developed mechanisms to downregulate the immune response 
when the pathogen is destroyed. Activated T cells can be suppressed by regulatory T 
cells (Tregs) that are defined by a CD4+CD25high phenotype and expression of 
transcription factor  FoxP3 [77]. These cells are induced by TGFȕ and IL-2 and secrete 
the signature cytokines IL-10 and TGFȕ [77]. Reduced numbers of Treg cells is the 
characteristic feature of the most autoimmune diseases. Decreased Treg numbers 
correlate negatively with disease activity in SLE patients [180]. Moreover, functions of 
these cells are impaired during SLE flares due to so far unknown reasons, but are 
restored during SLE remission [181].  Numbers of Tregs are reduced in the skin lesions 
of CLE when compared to other inflammatory skin diseases [182]. Aberrant function 
and/or low numbers of Tregs could partly explain hyperactivity of other types of T cells 
in LE. 
 
3.5.3 B cells and LE 
 
Presence of autoantibodies is the hallmark of SLE and this fact emphasizes the 
importance of B cells in pathogenesis of this disease [2]. B cell-produced 
autoantibodies lead to formation of ICs that are deposited in the target organs and 
induce inflammation and tissue damage [183]. B cell homeostasis seems to be aberrant 
in SLE patients: the circulating B cells are generally more activated as they express 
more costimulatory markers. The typical B cell profile in SLE is expansion of 
immature and memory B cells and plasma cells [183]. B cell activation factor 
BAFF/BLyS is important for B cell maturation, activation and differentiation and is 
produced by phagocytes or stromal cells of secondary lymphoid organs. Increased 
levels of BAFF are detected in the sera of lupus patients [184]. In an animal model, 
mouse transgenic for BAFF, but lacking functional T cells, still develop lupus-like 
disease due to the activation of B cells [185].  
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The important role of B cells is confirmed by using a B cell-depleting agent, 
Rituximab that can successfully induce remission in a substantial proportion of SLE 
patients with vital organ involvement [186]. In addition, a new compound affecting B 
cell activation via blockade of BAFF/BlyS has been recently approved for treatment 
of SLE patients and is on its way to the market [187].  
 
 
In conclusion, this short overview of the major players of the immune system 
demonstrates the complexity of the autoimmunity in lupus. More research is still 
needed to understand why and how attack against self occurs.  
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4 AIMS OF THE THESIS 
 
Lupus erythematosus (LE) is a prototype systemic autoimmune disease defined by 
abnormal activation of the immune system against ubiquitously expressed intracellular 
proteins and production of autoantibodies directed against them. Skin is an organ 
commonly targeted by the autoimmune inflammation in LE. Many of LE patients are 
photosensitive and exposure to the sun can trigger development of CLE lesions. A 
proportion these patients display anti-Ro52 autoantibodies. CLE lesions can also be 
induced using artificial sources of UVR. Skin is an easily available organ for biopsy 
acquisition and combined with experimental photoprovocation provides a valuable 
opportunity to investigate the cellular and molecular events occurring during CLE 
lesion development.  
 
This thesis aimed to define molecular events occurring in the skin during development 
and healing of UVR-induced CLE lesions, and also to investigate if the autoantigen 
Ro52 is expressed in the CLE target organ and to define what molecules modulate its 
expression.   
 
The specific aims were: 
 
- To assess if a standardized photoprovocation protocol is a suitable and reproducible 
method for multicenter phototesting studies of CLE patients 
 
- To investigate the dynamics of cytokine expression in UVR-induced developing and 
healing CLE lesions   
 
- To investigate if the autoantigen Ro52 is expressed in the CLE target organ and to 
explore the dynamics of its expression in UV-induced developing and healing lesions 
 
- To investigate what biological factors could modulate the expression and cellular 
localization of Ro52  
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5 RESULTS AND DISCUSSION 
 
5.1 PHOTOPROVOCATION IN CLE: A MULTICENTER STUDY 
 
5.1.1 Rationale, background and methodological considerations 
 
Sun exposure can trigger CLE and artificial UVR sources can be utilized for 
experimental induction of such lesions. Experimental photoprovocation is a valuable 
scientific resource allowing study of the pathogenesis of UVR-induced CLE [17, 
188]. The investigator can follow the clinical symptoms of the developing lesions and 
acquire skin biopsies for the exploration of the ongoing cellular and molecular 
processes. In clinical practice, experimental photoprovocation might be utilized for 
verification of the reported or suspected photosensitivity and in order to differentiate 
CLE from other photodermatoses [189]. 
 
The very first attempts to artificially induce CLE lesions using UVR were described 
in 1929 by Fuhs (reviewed in [11]). Photoprovocative studies were performed and 
described by several research groups [188, 190]. Their results allowed important 
advances in understanding the prevalence of photosensitivity among different CLE 
subtypes and importantly, cellular and molecular aspects of UVR role in the 
pathogenesis of this disease. Photoprovocation is a complex procedure. Several 
methodological aspects must be taken into account when planning a study to allow 
maximal benefit of this rewarding, but resources-demanding procedure [18, 188, 190-
192].  
  
The photoprovocation procedure 
 
Photoprovocation is a time-consuming procedure and requires multiple visits to the 
unit. The obligatory points of a common protocol include: recording patient’s history 
and general clinical assessment followed by threshold phototesting with UVB and/or 
UVA on day 1; readout of MED and MTD (please see below for more details), and 
estimation of the UVR dose to be used, as well as the first photoprovocation on day 2; 
on days 3 and 4 subsequent photoprovocations are performed, with the same or 
different UVR dose, as initially decided (figure 5). Furthermore, the irradiated area is 
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assessed clinically on every other-to every fourth day, up to 30 days. Importantly, the 
follow-up must be longer than 3 weeks since CLE lesion development usually occurs 
with a certain delay [188].  
 
 
Figure 5. (a) An example of a schedule for a photoprovocation procedure. (b) An 
example of an experimentally UVR-induced CLE lesion (from paper II, figure 3). 
 
MED and MTD 
 
Sensitivity to UVR is a complex feature and differs between individuals, partly due to 
the skin phototype [193]. Individual sensitivity to UVR can be assessed by estimating 
minimal erythema dose (MED) and/or minimal tanning dose (MTD). MED is actually 
the minimal UVB dose inducing sunburn. MED is defined as the lowest dose of UVB 
that induces barely perceptible erythema with well-distinguished edges [193]. In 
practice, MED is assessed by irradiating small skin areas with increasing doses of 
UVB and determined after 24 hours according to the above described definition. 
MTD (sometimes denoted minimal persistent pigment darkening (MPPD)) dose is 
determined accordingly, but for UVA. MTD is defined as the UVA dose that induces 
skin pigmentation with clear demarcation [188, 190]. MED and MTD are usually 
estimated before the start of experimental photoprovocation. The determined MED 
and MTD are used to calculate the UVA and UVB doses to be applied in the study. 
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Dosing of UVR 
 
CLE-resembling lesions can be reproduced using UVB, UVA or a combination of 
both [188, 191]. The UVR dose to be used should be calculated by the estimated 
MED and/or MTD, and usually 2- or 3- fold MED, and/or 1 MTD that is applied 
[188, 190, 191]. Doses of UVA needed to induce lesions are much higher than those 
of UVB since UVA has less energy. The majority of published reports indicate that in 
order to induce a CLE-resembling lesion photoprovocation must be performed on two 
or three subsequent days, since single exposure seldom leads to lesion development 
[188, 194, 195]. It has been argued that provocation with a combination of UVA and 
UVB is the most relevant to use as it resembles the spectrum of radiation emitted by 
the sun.  
 
Table 5 
A proposal on a standardized protocol for UVR photoprovocation 
Criteria  Proposal and motivation 
Choice of subject SLE patient preferentially in remission or low disease 
activity  
No need to involve only patients with a history of 
photosensitivity 
Preferentially no systemic medication for the cutaneous 
disease during the whole photoprovocation and follow-up 
Season Preferentially not in summer, due to a risk for influence of 
outdoors sun 
UVR source Combined UVB and UVA lamp that emits radiation close 
to that emitted by the sun on a sunny summer day 
Pretesting Determination of MED and MTD 
Dosage Calculated as assessed by MTD and MED. Usually 75-100 
J/cm2 of UVA and 1.5 MED of UVB on 3 consecutive 
days 
Anatomical location Preferentially upper back, since this is the location where 
spontaneous lesions frequently occur but also upper back 
has lower risk for daily sun exposure and is associated 
with less cosmetic discomfort after the provocation is over 
Size of test area At least 4x5 cm, as photoprovocation on smaller fields is 
often associated with negative results  
Evaluation and follow-up Daily on day 1, 2, 3 and then every 3-4 days up to 4 weeks 
after the last irradiation 
Criteria for a positive test Skin lesions resembling CLE in their clinical appearance 
and histopathological changes 
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Anatomical localization and size of the area 
 
Spontaneous lesions predominantly occur in the skin areas frequently exposed to the 
sun such as face, ears, neck, décolleté, upper back, extensor aspects of the arms and 
forearms as well as dorsal aspects of the hands. Most investigators choose the upper 
back or extensor aspects of overarms for provocative irradiation due to practical and 
cosmetic reasons [17, 188]. Investigators who performed photoprovocations on other 
anatomical locations could hardly induce CLE lesions [194, 195]. The size of the 
photoprovoked skin area must be at least 4-6 cm x 5-10 cm in order to induce CLE 
lesions [18, 188, 190, 191, 194, 196].  
 
The most important aspects of the photoprovocation procedure are summarized in 
table 5 [17, 63, 188, 191, 194, 197]. 
 
5.1.2 Multicenter photoprovocation study 
 
In paper I we aimed to evaluate if photoprovocation is a reproducible method to 
assess photosensitivity in CLE patients. In study I we included 47 CLE patients (14 
with SCLE, 20 with DLE, 13 with LET) and 13 healthy volunteers. None of the 
patients filled the ACR criteria for SLE. All subjects underwent photoprovocation at 
7 European sites (Sweden, Germany, Scotland and Poland). On day 1 all subjects 
underwent threshold testing with UVA and UVB irradiation. On day 2 MTD for 
UVA and MED for UVB were estimated for each subject. Thereafter, each subject 
was irradiated daily on uninvolved skin on the upper back with their MTD (UVA) on 
day 1 followed by 1.5 MEDs (UVB) on day 2 and 3. UVR exposed areas were 
assessed for LE-specific skin lesions on days 2-32. Twenty-two (47%) CLE subjects 
(57% of SCLE, 35% of DLE and 54% of LET patients) and none of the healthy 
volunteers developed clinically CLE resembling lesions (paper I, figure 2). Nineteen 
(86%) of these lesions had histopathological changes compatible with CLE. 
Fitzpatrick’s phototype I or II were more common (86% vs. 52%) among CLE 
subjects who developed lesions and they also had significantly lower mean MED 
(p=0.004) (paper I, figure 1, table 1 and 2). The majority (93%) of all included 
patients were positive for ANA. Prevalence of anti-dsDNA was low (14%). Anti-
Ro/SSA positivity was detected in 71% of SCLE patients, 21% of DLE patients, but 
none of LET patients had these autoantibodies. CLE subjects who developed lesions, 
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had twice as long time from their last CLE flare when compared to those who were 
non-responders (9.5 vs. 5 months) (paper I, table 2). Eight CLE patients were treated 
with antimalarials and continued the treatment during the study. Only 2 (25%) of 
these subjects developed lesions, in comparison to 20 (51%) responders in the 
systemic immunomodulatory medication-free group. Nineteen of those 20 subjects 
who were not exposed to anti-malarials and developed lesions were smokers (95%). 
In the non-responder group smoking was less prevalent (68%) (paper I, table 1).   
 
The number of participants reporting adverse events (AE) were highest among CLE 
lesion-positive subjects (59%), followed by lesion-negative patients (36%) and 
controls (31%) (paper I, table 3). Most of the AE were negligible. Seven CLE patients 
developed CLE-associated AE. Four of those were photoprovocation-positive and 3 
photoprovocation-negative subjects. In 4 patients changes in their pre-existing lesions 
were observed. New CLE lesions, developing outside the irradiated area, were noted 
in 3 study subjects.  
 
There was no significant difference in photoprovocation results between the study 
sites and no clinically significant differences in safety were observed between CLE 
subjects and healthy volunteers following the photoprovocation.  
 
5.1.3 Discussion 
 
In study I we present results of a multicenter photoprovocation study in which 22 
CLE patients (47%) developed UVR-induced skin lesions clinically resembling CLE. 
The patients with the diagnosis of SCLE had the highest rate of positive result (57%), 
followed by LET (54%) and DLE (35%). The previously reported rate of overall 
positive results (all CLE subtypes as a group) varied between 25-93%. Among the 
subtypes of CLE, these proportions ranged following: 25-85% for SLE/ACLE, 50-
100% for SCLE, 10-64% for DLE/CCLE and 50-76% for LET/ICLE [17, 188, 191, 
196, 197]. The variations in the results reported by these studies most probably 
depend on the natural photosensitivity of the included subjects but also some 
methodological differences. Investigators who used ‘high intensity’ protocols (e.g. 
increased the UVR doses during the ongoing study and performed irradiations on 
more than 3 following occasions) reported the highest rates of positive results 83-
93% [191, 196]. It is of importance that prevalence of the photosensitivity varies 
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among CLE subtypes and the numbers of the included patients with different CLE 
subtypes must be taken into account when comparing these results in general. SCLE 
and LET are the most photosensitive entities as previously reported and confirmed by 
our results [17, 31, 189]. 
 
The observation that those CLE subjects who had a relatively recent flare less often 
developed a positive phototest result is interesting and has not been reported before. It 
could be the case that those who had a recent flare and had been on systemic 
medication that was discontinued before the study start, still had a suppressed 
immune system and therefore were protected from the effects of UVR. This 
explanation is very probable, since the half-life of hydroxychloroquine, which had 
been used by some patients before the study start, is more than 40 days [198].  
 
Several investigators reported that CLE patients are more susceptible to sunlight in 
general as assessed by MED. Our results confirm this finding, especially in the 
phototest-positive DLE and LET patients (paper I, table I) [17, 195, 197]. SCLE is 
the most photosensitive subtype according to our data, but interestingly these patients 
had higher MED than the two other groups (paper I, table 2). Evidently, there are 
some other factors of importance that determine the lesion development after 
exposure to UVR in this subgroup of patients. The most distinct feature of SCLE is 
the high prevalence of anti-Ro/SSA autoantibodies (71% in our group). The available 
data indicate that these autoantibodies are indeed pathogenic in the induction of 
clinical manifestations of NLE, including SCLE-resembling lesions [199, 200]. The 
risk of NLE manifestations wanes after 6 months of age as maternal IgG, and also 
anti-Ro/SSA autoantibodies, are cleared from circulation. These facts strongly 
suggest that these autoantibodies could also be associated with the UVR induced 
SCLE lesions in adult patients. Several studies reported that patients who carry anti-
Ro/SSA autoantibodies develop a pathological reaction to photoprovocation more 
often [4, 5, 17, 188]. We could however not confirm this association in our study 
group at a statistically significant level, most probably due to a smaller sample size. 
 
The history of smoking was associated with a positive phototest result in the patient 
group who were not on any immunomodulatory systemic medication (95% smokers 
in the phototest positive group, vs. 68% smokers in non-responders group) (paper I, 
table I). It was previously reported that smoking is associated with CLE and 
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especially in those with complement deficiencies [33, 72]. Interestingly, smokers 
usually have lower anti-Ro/SSA autoantibody levels. Tobacco smoke could therefore 
act as an independent trigger of CLE without the necessity of autoantibodies [24].  
 
Our study included 8 individuals who were treated with antimalarials and 2 of them 
(25%) developed CLE lesions after photoprovocation. The rate of positive phototest 
was 51% in the group of CLE subjects without any systemic medication. These 
findings suggest that antimalarials could be protective in this context (25% of vs. 
51% ), but does not supress this risk completely. There were two CLE subjects who 
developed lesions despite treatment with antimalarials and they both were smokers. 
Our sample size was small, but it was previously reported that CLE diagnosed 
smokers have less good responses to anti-malarial treatment and maybe, also less 
protection from photosensitivity [73]. Importantly cessation of smoking may re-
establishe sensitivity to anti-malarials and counseling on smoking cessation is 
therefore of major importance [33, 73].  
 
Our study included only CLE subjects with a history of photosensitivity, but previuos 
reports indicate that CLE lesions can be induced in 58% of patients who negate 
history of photosensitivity [188]. Investigators should therefore not be discouraged 
from inclusion of such patients in the experimental phototesting studies.   
 
Approximately half of the included subjects reported AE, but most of them were 
negligible (paper I, table III). Seven patients developed CLE-associated AE, 4 of 
them were photoprovocation-positive and 3 non-responders. In 3 of them these 
included small clinical changes in the preexisting lesions. In one subject the changes 
in the previous lesion required topical therapy. Three patients developed new lesions 
outside the irradiated area. Low rate of AE with minor or moderate severity and 
similar rates between responders and non-responders to the phototest (4 vs. 3) 
indicates that CLE-associated AE were most probably due to the natural course of the 
disease. None of the subjects developed symptoms compatible with SLE diagnosis in 
our study, in which only CLE patients were included. No cases of exacerbations of 
systemic disease were reported in those photoprovocation studies that included 
subjects with SLE [17, 190, 196, 197]. One negative aspect of the photoprovocation 
is that the induced lesion may heal leaving temporary hypo- or hyperpigmentation 
associated with certain cosmetic discomfort [188]. 
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5.1.4 Concluding remarks and future perspectives  
 
Our results indicate that photoprovocation is a reproducible and safe method with 
overall positive results in approximately 50% of the participating patients and is a 
suitable tool for utilization in multicenter studies and clinical trials. 
 
Much of the available knowledge about the pathogenesis of sun-induced CLE comes 
from such studies ([59, 63, 201] and paper II). To understand the pathogenesis of 
CLE, it is of major interest to delineate the primary and subsequent biological events 
occurring in the skin post-UVR exposure. An additional method that could provide 
direct insight into the biological processes occurring in the skin following UVR is 
microdialysis, which is already used in the field of dermatology and is less invasive 
than skin biopsy acquisition [202, 203]. Sample acquisition via a microdialysis 
catheter inserted in the skin prior, during and directly after UV irradiation could allow 
investigation of the biological processes taking place in real time. Recognition of 
these processes would provide a better insight into the primary events in the irradiated 
skin and could guide the development of future sun-screens and medications. 
 
5.2 THE ROLE OF HMGB1 IN UVR-INDUCED CLE 
 
5.2.1 Rationale, aims and methodological approach 
 
Our group has previously demonstrated that HMGB1 is expressed at the site of local 
inflammation in spontaneous lesions of CLE patients, and that it is accompanied by 
strong upregulation of other cytokines such as TNF-Į and IL-1ȕ [84]. 
 
In study II we therefore aimed to define the relation between the expression of  
HMGB1, TNF-Į  and IL-1ȕ and the clinical activity of developing and healing CLE 
lesions induced experimentally by UVR. For this study we used a collection of 
sequential skin biopsies obtained during a photoprovocation study described previously 
by Nyberg et al. [17, 18]. For the current study sequential biopsies from 9 CLE patients 
and 2 healthy controls were available. Skin specimens were sectioned and stained using 
immunohistochemistry (IHC) with rabbit polyclonal anti-HMGB1, mouse monoclonal 
anti-TNF-Į and anti-IL-1ȕ antibodies (Abs). The expression of cytokines was assessed 
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by two investigators in a blinded semi-quantitative manner validated previously [84]. 
During assessment the skin section was divided into two different observational areas: 
epidermis and dermis. The distribution of HMGB1 was assessed in three different 
compartments: the cell nucleus, cytoplasm, and extracellular space. Slides stained for 
TNF-Į and IL-1ȕ were assessed for the proportion of stained cells within the dermal 
infiltrate, since no or very little expression in the epidermis was noted.  
 
We chose to perform a manual analysis of the immunohistochemical stainings and did 
not use a computerized image analysis, even though it might be a less biased method 
for some purposes. The aim of our study was to analyze the subcellular localization of 
the protein of interest (HMGB1 in study I and Ro52 in study II), and there was no 
available software that could differentiate between the nuclear, cytoplasmic and 
extracellular staining. Therefore we chose a manual method and slides were assessed in 
a blinded manner by two investigators. The assessment results of each section were 
compared between the observers and if the difference was greater than 20% such slides 
were discussed and reassessed until the values were agreed upon within the variation of 
20%. This method was utilized in previous studies published by our group [84]. The 
staining of TNF-Į and IL-1ȕ was assessed by manually estimating the proportion of the 
stained cells. Other investigators reported that such manual assessments provide a 
satisfactory correlation with the results of computerized image analysis [204]. 
 
5.2.2 Results 
 
In paper II we demonstrate that HMGB1 was expressed weakly in unaffected skin with 
predominant nuclear localization in the basal and adjacent layers of epidermis and skin 
appendages, and in the endothelia within the dermis. In the active CLE lesions up to 
50% of epidermal cells and more than half of the cells comprising dermal infiltrates 
stained positively for HMGB1. Furthermore, an increase in the dermis infiltrating cells 
positive for cytoplasmic HMGB1 was observed in the active lesions. These numbers 
decreased as lesions faded (coefficient of concordance (c.c.) = 0.75, p<0.05). 
Translocated extracellular HMGB1 was detected in both dermis and epidermis in the 
active CLE lesions and cleared in healing lesions (c.c. = 0.80, p<0.05 and c.c. = 0.48, 
p<0.005, respectively) (figure 6 and paper II, figure 2 and 3 and table 1).  
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Interestingly, in a few patients for whom early biopsies were available, an increase in 
HMGB1 expression and transfer from cell nucleus was noted early in the course of 
lesion development, while the highest expression and extracellular deposition 
corresponded to the clinically most active inflammation. Additionally, some 
extracellular HMGB1 was still observed in the healing lesions (figure 6 and paper II, 
figure 2).  
 
The proportion of IL-1ȕ positive cells detected in the most active lesions varied 
substantially among individuals. Unexpectedly, the highest expression of IL-1ȕ was 
observed in the healing lesions. TNF-Į expression was upregulated in the active lesions 
of 6 CLE patients, but the other 3 out of 9 investigated (33%) patients displayed almost 
no TNF-Į in the biopsies acquired from active lesions. In the healing lesions, we did 
not observe any particular pattern of TNF-Į expression, since individual variation of 
expression was substantial (figure 6 and paper II, figure 4). 
 
In healthy individuals up to 30% of all epidermal cells stained positively for nuclear 
HMGB1. The nuclear staining decreased in abundance and a weak cytoplasmic staining 
was observed in the epidermal cells, but no or little extracellular HMGB1 was detected 
in the biopsies acquired 3 days after the last exposure to UVR. Photoprovocation 
resulted in the appearance of some IL-1ȕ positive cells in the dermis, but presence of 
TNF-Į was not detectable (paper II, figure 5). 
 
We also tested whether HMGB1 complexed to LPS could induce Ro52 upregulation 
or translocation in primary human keratinocytes in vitro, but no such changes were 
observed (unpublished preliminary results) using the conditions described by others 
[109].
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Figure 6. HMGB1, IL-1ȕ and TNFĮ expression patterns in unaffected and 
photoprovoked skin. 
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5.2.3 Discussion  
 
In paper II we demonstrated that increased numbers of keratinocytes express HMGB1 
in the cell cytoplasm in the clinically most active CLE lesions. It might be the case that 
UVR itself or cytokines induced by it caused this induction [102]. It was previously 
reported that it is mainly activated cells that increase synthesis of HMGB1 and 
translocate it to the cell cytoplasm, which subsequently leads to HMGB1 secretion [99, 
205]. Our results suggest that keratinocytes can upregulate HMGB1 in response to a 
proinflammatory stimulus. The observed increase in extracellular HMGB1 within the 
epidermis invites a hypothesis that epidermal keratinocytes might be able to actively 
secrete HMGB1. In addition, extracellular HMGB1 observed in the basal and adjacent 
layers of the lesional epidermis, might have been passively released. UVR induces 
apoptosis of keratinocytes and clearance of these cells is impaired in a substantial 
proportion of LE patients [59, 60] and remarkably, extracellular HMGB1 may also 
contribute to impaired removal of apoptotic cells via binding to phosphatidylserine and 
impeding recognition of apoptotic cells [206]. Non-removed apoptotic keratinocytes 
most probably undergo secondary necrosis and passively release HMGB1 bound to 
chromatin [60, 95, 115]. Consequently, the extracellular HMGB1 observed in the 
epidermis of CLE lesions might be a product of activated keratinocytes and secreted as 
cytokine and/or passively released from secondary necrotic cells.   
 
An increase of cells with cytoplasmic HMGB1 was observed in the dermis of the most 
active CLE lesions. In parallel, staining for extracellular HMGB1 expanded. Previous 
studies indicated that activated macrophages/monocytes are the cells producing this 
cytokine in rheumatoid arthritis synovia [207]. CD68+ macrophages are present among 
other dermis infiltrating cells in CLE lesions [90] and it is therefore probable that the 
cells with strong cytoplasmic HMGB1 expression are activated mononuclear 
phagocytes readily secreting HMGB1.  
  
In summary, we suggest that the extracellular HMGB1 observed in CLE lesions might 
have been actively secreted by keratinocytes or mononuclear phagocytes. In addition, a 
portion of the observed HMGB1 might have been released from secondary necrotic 
keratinocytes.  
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Extracellular HMGB1 may act as a proinflammatory cytokine and further amplify the 
production of other cytokines, such as TNF-Į, IL-1ȕ and IL-6, by mononuclear 
phagocytes [102]. In addition, cells respond to the presence of these mediators by 
further enhancing HMGB1 synthesis and secretion [101]. This self-escalating 
proinflammatory loop of the cytokine induction might be consistent with the extended 
pro-inflammatory response to UVR which is evident in CLE patients. Interestingly, IL-
1ȕ expression was not that extensive in the most active UVR-induced lesions as 
previously observed in the spontaneous CLE [84]. This could reflect a biological 
difference in the nature of UVR-induced transient and the longer-lasting spontaneous 
lesions, but might also indicate that HMGB1 is a more important factor in the 
development of CLE lesions.  Subsequently to our publication it was discovered that 
HMGB1 builds complexes with IL-1ȕ [109]. It is possible that we have underestimated 
detection of this cytokine by IHC using monoclonal antibodies since the specific 
epitope might have been hidden in the IL-1ȕ-HMGB1 complexes. In our study, TNF-Į 
expression was increased in more than half (66%) of patients with active lesions, but 
almost totally absent in the additional three. This finding is not consistent with 
previously reported TNF-Į upregulation in all spontaneous CLE lesions. Our finding 
that HMGB1, but not TNF-Į or IL-1ȕ upregulation mirrors the clinical activity of the 
UVR-induced lesions suggests that HMGB1 might really be an important mediator of 
inflammation in CLE [84].  
 
HMGB1 released from secondary necrotic cells is highly immunogenic and was 
demonstrated to incite autoimmunity in experimental settings [95, 115]. HMGB1-
nucleosome complexes released from secondary necrotic cells might induce maturation 
of antigen presenting cells [115] and, when opsonized by circulating immunoglobulins, 
stimulate IFNĮ secretion in pDC [208]. Moreover, such ICs were demonstrated to 
induce autoreactive B cell activation and anti-dsDNA autoantibody production in a 
mouse model [115, 116]. As deposition of ICs is a common finding in CLE at the 
dermo-epidermal junction (DEJ) it is therefore possible that extracellular HMGB1 
observed in this zone forms such complexes: HMGB1-nucleosomes-Ig. 
 
We have also observed the presence of extracellular HMGB1 in the late CLE lesions.  
HMGB1 has important functions in cell migration and chemotaxis and might therefore 
be involved in the healing processes [102]. The functional HMGB1 receptors RAGE, 
TLR4, TLR5 and TLR9 are expressed on keratinocytes and phagocytes within the skin, 
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and HMGB1 can be expected to exert its chemotactic and pro-inflammatory functions 
locally [209, 210]. 
 
5.2.4 Conclusion 
 
To conclude, in paper II we demonstrate that HMGB1 is strongly upregulated and 
translocated in UVR-induced CLE lesions, and that the highest expression coincides 
with the peak of the clinically activity of these lesions. High proinflammatory activity 
of HMGB1 alone or in complexes with other molecules, might play an important role 
in the induction and amplification of the inflammatory processes taking place in the 
UVR injured skin of CLE patients. In addition, HMGB1 observed in the late lesions 
might have a role in the process of healing. The role of TNF-Į and IL-1ȕ seems to be of 
less importance in this setting. 
 
5.3 Ro52 IN LE 
 
5.3.1 Rationale, aims and methodological approach 
 
Since Ro52 is a common target of circulating autoantibodies in lupus it is of major 
interest to understand which tissues and cells within them express this protein and 
under what conditions, as well as what cellular function the protein has and how it can 
become an antigenic target.   
 
Attempts to investigate the expression of Ro52 in different organs have been made, but 
these studies have relied on the detection of mRNA or use of human autoimmune sera 
[122, 138, 211-213]. Monoclonal autoantibodies (mAbs) to Ro52 were lacking and 
specific anti-sera raised by immunization with the antigen have been difficult to obtain 
due to the folding properties of Ro52 [121, 214]. Even if sera is claimed to be 
monospecific there is an obvious risk of contaminating specificities. Attempts to 
affinity purify against Ro52 have proven difficult due to the folding properties of the 
protein and may also be associated with loss of antigenic reactivity [121]. After careful 
biophysical characterization of Ro52 [121, 214], our group was successful in 
generating mouse hybridomas producing a panel of anti-human Ro52 mAbs [137]. In 
paper III we aimed to confirm the specificity of the selected hybridomas and to 
investigate Ro52 expression both in spontaneously occurring inflammatory skin 
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diseases as well as UVR-induced CLE. As a tool to detect Ro52 we utilized a panel of 
four selected mAbs: one mAb recognizing a Zinc finger motif and three mAbs 
detecting different peptides within the CC domain [137].  
 
First we confirmed the specificity of the mAbs by Western blot and ELISA (paper III, 
figure 1). We preferentially intended to use formalin-fixed paraffin embedded skin 
biopsy material, since this method is superior in preserving morphology. A problem 
associated with this fixation method is the crosslinking of antigenic epitopes by 
hydroxy-methylene bridges [215]. Consequently, antigenic epitopes become 
inaccessible to mAbs. A solution for this problem is antigen retrieval (AR). We tested 
several AR protocols. The AR was performed in citrate buffer at pH 6 in all 
experiments. The explored AR conditions included heating in the microwave for 5-10 
min three times and changing buffer between the heating procedures. This method gave 
inconsistent results, probably due to the fact that microwave heats the fluid in a non-
homogenous fashion. Heating on the stove provided easier controllable conditions and 
AR was performed at 95-100 ƕ C. Different durations of heating were tested: 10 min, 20 
min and 40 min. Active cooling by immersing the specimens in PBS at 24ƕ C was tested 
against passive cooling in the buffer of retrieval, until 24ƕ C was attained. Cooking in 
citrate buffer at pH 6 at 95-100ƕ C for 40 min followed by passive cooling provided the 
best and the most consistent results and was utilized for AR of the whole sample of 
paraffin embedded skin specimens. After the AR method was established, the 
suitability of four mAbs for immunohistochemistry was determined using different 
methods for tissue preservation and fixation. As indicated in figure 2 of paper III all 
four tested mAbs provided similar staining patterns in paraffin embedded, as well as in 
fresh-frozen, acetone fixed samples. Pre-incubation of autoantibody with the full length 
Ro52 overnight resulted in loss of the staining in IHC and detection in ELISA (paper 
III, figure 1).  
 
5.3.2 Results  
 
After we had developed the IHC protocol and confirmed that the staining pattern was 
the same with all four anti-Ro52 mAbs, we utilized one anti-Ro52 mAb recognizing a 
sequence within the CC domain of Ro52 to investigate the expression of this protein in 
CLE and other inflammatory skin diseases. We also aimed to determine whether UVR 
could modulate expression of this autoantigen.  
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Ro52 was upregulated in all CLE lesions (paper III, figure 2 and 3). Ro52 expression 
was increased in the epidermis of spontaneous CLE lesions as compared to control 
biopsies from unaffected skin of the same individual or healthy controls (paper II, 
figure 3). About 80% of the cells in the dermal infiltrates were also positive for Ro52. 
In uninvolved skin of patients and healthy controls Ro52 was mainly expressed in the 
epidermal cell nuclei, cytoplasmic expression being weak (paper III, figure 3). 
Upregulation of cytoplasmic Ro52 was observed in the epidermal cells of both 
spontaneous and UVR-induced CLE lesions (paper III, figure 3 and 5). Interestingly, in 
a proportion of patients we could observe an intense staining for Ro52 in the basal cell 
layer (paper III, figure 2 and 3). Moreover, UVR exposure induced Ro52 upregulation 
in human keratinocytes in vitro within 24 h (paper III, figure 6) as demonstrated by 
immunocytochemistry and qPCR. The staining revealed that Ro52 was predominantely 
located to the cytoplasm of the cultured cells and UVR did not influence its subcellular 
localization. 
 
Importantly, strong Ro52 expression was observed in all CLE lesions investigated 
(ACLE, SCLE, DLE) independently of CLE subtype and presence or absence of anti-
Ro/SSA autoantibodies. Unexpectedly, relatively similar upregulation of Ro52 was 
detected in the epidermis and dermal infiltrates of LE-nonrelated inflammatory skin 
diseases such as psoriasis, atopic eczema and lichen planus (paper III, figure 4). 
 
5.3.3 Discussion  
 
We observed a strong upregulation of Ro52 in the cytoplasm of epidermal cells in both 
spontaneous and UVR-induced CLE skin lesions. Intensive staining for Ro52 was 
observed in the basal and adjacent keratinocytes in a proportion of patients. This zone is 
a common target of autoimmune attack and that is where the most of apoptotic 
keratinocytes reside [14]. We also demonstrated that keratinocyte exposure to UVR 
upregulate Ro52 expression in vitro. The biological mechanism underlying this event is 
not known. Since Ro52 is an IFN-inducible protein and UVR exposure has been 
demonstrated to activate IRF7 in other cell types, it is therefore possible that a 
temporary IFNĮ production occurs, which could subsequently lead to the induction of 
Ro52 transcription [134, 137, 216]. Increased levels of Ro52 might be needed to 
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terminate the UVR-induced cutaneous inflammation, as Ro52 was demonstrated to act 
as a negative regulator of inflammation [129, 131].  
 
The expression of Ro52 is upregulated in CLE lesions and, in parallel, many signs of 
ongoing cutaneous inflammation are present in parallel, including upregulation of IFN-
inducible proteins [63, 64]. One could speculate that Ro52 is incapable to act as a 
negative feedback regulator in CLE/LE patients. Genetic polymorphisms in the Ro52 
gene have been associated with SLE and anti-Ro52 autoantibody production in SS, 
although it is not known whether these polymorphisms affect the quality or levels of 
Ro52 expression [45, 46]. Interestingly, our group has recently demonstrated that 
patient-derived anti-Ro52 autoantibodies directed against the RING domain of Ro52 
inhibit its E3 ligase activity in vitro. The inhibition occurs through steric hinderance by 
blocking the access of the E2 to its binding site in the RING domain (Espinosa et al, 
submitted). It is therefore possible that Ro52 autoantibodies do interfere with the 
function of their target in vivo. Alternatively, another molecule involved in the Ro52 
ubiquitination pathway could be aberrantly expressed in lupus patients and impede 
Ro52 function (for example IRF5 and polymorphisms in this gene have been identified 
in SLE and CLE patients) [42, 217]. 
 
UVR-induced upregulation of Ro52 might also contribute to the anti-Ro52-directed 
autoimmunity. Forced expression of Ro52 in a lymphoma-derived B cell line leads to a 
decreased rate of proliferation and increased susceptibility to activation-induced cell 
death [123]. The increased Ro52 expression in the basal keratinocytes of CLE lesions 
could therefore, at least partly, account for the high numbers of apoptotic cells typically 
found by histopathology [14]. Several investigators have reported that keratinocytes 
translocate Ro52 (accompanied by other common LE autoantigens) to the apoptotic 
blebs after exposure to UVR in vitro [65-67]. A hypothesis was therefore suggested that 
this is how the autoantigen Ro52 could be exposed to the immune system. As a 
substantial part of LE patients have defects in removal of unviable cells [60, 156], we 
assume that Ro52 might be also released by secondary necrotic cells and importantly, 
the increased Ro52 production in the basal keratinocytes just before the cell death could 
contribute to an overwhelming load of this autoantigen. Presence of Ro52, together 
with other highly proinflammatory molecules (eg HMGB1-nucleosome complexes, 
cytokines ([115] and paper II)) in the surrounding, could therefore facilitate maturation 
of the professional APCs, uptake of the autoantigen Ro52 and its presentation to the 
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anergic or low-reactive T and/or B cells. Subsequently, this mechanism could lead to 
the induction of the adaptive immunity against Ro52 in a genetically susceptible 
individual.  
 
Interestingly, James et al. have proposed a hypothesis on how anti-Ro52 autoantibodies 
might contribute to the deposition of ICs in the target organs and impede their clearance 
[135]. They suggested that extracellular Ro52, for example released from secondary 
necrotic cells, could bind Fc part of any locally available IgG. In patients with anti-
Ro52-positive disease such Ro52-IgG complex could be additionally bound by 
autoantibodies against other epitopes of Ro52 and thus lead to formation of huge ICs 
[135]. Authors suggest that such ICs could be difficult to recognize via FcȖR or 
complement receptors and they could account for ICs deposits observed in CLE skin 
lesions and lupus nephritis [36, 218].  
  
We found equivalently strong Ro52 expression in the skin lesions of all CLE subtypes 
(ACLE, SCLE and DLE) investigated independently to their anti-Ro52 autoantibody 
status. Moreover, corresponding Ro52 upregulation was also observed in the skin 
lesions of other LE-unrelated inflammatory skin diseases. These findings prompt a 
hypothesis that Ro52 has a more general regulatory role in the inflammation, but 
function of this protein is probably impaired in at least a subgroup of LE patients. This 
assumption is further supported by the recent report on an animal model in which lack 
of Ro52 leads to an uncontrollable inflammatory response to a minor skin injury that 
subsequently advances to the development of lupus-like disease [131].  
 
Approximately 80% of the dermal infiltrates comprising cells stained positive for Ro52 
[219]. It is known that a substantial part of these cells are activated CD4+ and CD8+ T 
cells and macrophages [90]. All these cells are able to express Ro52 [123, 131]. High 
Ro52 expression in macrophages and T cells has been demonstrated have dual effects: 
could enhance their proinflammatory properties, such as production of IL-12p40 and 
IL-2 respectively, but also negatively regulate their activation [128, 220]. 
 
5.3.4 Conclusion 
 
To conclude, our findings suggest that UVR can upregulate Ro52 expression in the 
CLE target cell keratinocyte. High Ro52 expression might sensitize keratinocytes for 
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cell-death inducing impulses and subsequently lead to an overwhelming load of this 
autoantigen upon secondary necrosis. Equivalent upregulation of the Ro52, lupus 
autoantigen, in LE-nonassociated inflammatory skin diseases indicates that Ro52 has a 
more general role in the regulation of cutaneous inflammation and high Ro52 
expression is not specifically associated with the presence of anti-Ro52 autoantibodies. 
Despite high expression levels, Ro52 may have impaired capability to act as a negative 
feedback regulator in LE patients. Increased IFNĮ production observed in many LE 
patients could be one of the negative consequences of the non-functional Ro52. 
 
5.4 NO MODULATES THE CELLULAR LOCALIZATION OF Ro52 
 
5.4.1 Rationale and aims  
 
Nitric oxide (NO) is a small and short-lived gaseous molecule belonging to a class of 
molecules termed reactive oxygen/nitrogene species (ROS) [58]. Keratinocytes 
constantly produce low levels of NO, but production can be enhanced by exposure to 
stress factors such as UVR [58]. This occurs via induction of the generating enzyme 
inducible nitric oxide synthase (iNOS) [62]. CLE patients have aberrant timing in iNOS 
expression in response to UVR [62]. Interestingly, it was previously demonstrated that 
exposure of cells to another ROS, hydrogen peroxide ( H2O2) or activating cytokines 
(IFNĮ) results in the nuclear enrichment of Ro52 [68, 137]. Ro52 has an E3 ubiquitin 
ligase activity and interacts with two ubiquitin conjugating enzymes located in the 
different cellular compartments: UBE2D1 (cytoplasmic) and UBE2E1 (nuclear), as it 
was demonstrated previously [123, 126]. Little is known about what intrinsic factors 
influence the cellular localization Ro52. Cytoplasmic localization of several other 
TRIM family proteins depends on their CC domains and some of them (e.g. TRIM27) 
are actively exported from the nucleus by Exportin-1 [221, 222].  
 
In study IV we therefore aimed to define what the natural factors that determine 
subcellular localization of Ro52 are and if NO could modulate subcellular localization 
of Ro52.  
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5.4.2 Results 
 
First we confirmed that both ubiquitin conjugating enzymes UBE2D1 and UBE2E1 
support Ro52-mediated ubiquitination (paper III, figure 1). Furthermore, we transfected 
HeLa cells with fluorescent reporter fused Ro52, UBE2D1 and UBE2E1. In these cells 
Ro52 and UBE2D1 were located in the cell cytoplasm under steady state conditions. 
UBE2E1 resided strictly in the cell nucleus and was enriched in the nucleoli (paper IV, 
figure 2). We proceeded by constructing GFP-Ro52 and several deletion mutants of 
GFP-Ro52 and expressed them in HeLa cells. GFP-Ro52 was located in the cell 
cytoplasm, while deletion of the CC or leucine zipper domains resulted in the nuclear 
accumulation (paper IV, figure 3). Deletion of the B30.2 domain in the leucine zipper 
lacking constructs abolished the nuclear localization. As Ro52 contains a hypothetical 
leucine rich exportation signal (NES) within the CC domain we therefore wanted to 
determine if Ro52 is exported from the nucleus via Exportin-1 mediated pathway that 
utilizes this sequence. Neither addition of leptomicin B, an inhibitor of the latter 
pathway, nor mutation of the putative NES had any influence on the typically 
predominant cytoplasmic localization of Ro52 (paper IV, figure 4).  
 
We further explored if NO could modulate subcellular localization of Ro52. Exposure 
to NO donor DETA-NANOate resulted in a relatively prompt (within 6 h) nuclear 
accumulation of Ro52 in both primary human keratinocytes and GFP-Ro52 transfected 
HeLa cells (paper IV, figure 5 and 6a). Importantly, cells expressing GFP-Ro52 with 
the mutated B30.2 domain retained the protein in the cytoplasm despite cell stimulation 
with NO. Our results indicate that the CC domain is important for the cytoplasmic 
retention of Ro52 and B30.3 for its ability to stay in the nucleus.  
 
Since NO displayed the ability to modulate subcellular localization of Ro52 in vitro, we 
proceeded to investigate the expression of Ro52 and iNOS in the skin biopsy material 
derived from CLE patients lesions. We detected iNOS positive cells in the epidermis 
and dermal infiltrates (paper IV, figure 6a). In adjacent skin sections cells with nuclear, 
but also cytoplasmic, Ro52 were present. It is thus possible that NO generated at the 
site of inflammation can modulate subcellular localization of Ro52 and influence in 
which cellular compartment Ro52 is operative as E3 ligase. 
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5.4.3 Discussion 
 
We determined that an intact CC domain, and in particular the leucine zipper within it, 
is important for the cytoplasmic localization of Ro52. When this region was deleted, 
Ro52 was translocated into the nucleus. Interestingly, an alternatively spliced transcript, 
Ro52ȕ that lacks the leucine zipper domain, was reported [223]. The reported genetic 
polymorphism in the intron 3 within the Ro52 gene is positioned close to one of the 
splicing sites used for generating Ro52ȕ [45]. This polymorphism is associated with 
anti-Ro52-positive SS, but has not been investigated in anti-Ro52 associated LE so far. 
Such a polymorphism could influence the amount of Ro52ȕ produced. If this would be 
the case, the amount of cytoplasmic/nuclear Ro52 could be expected to shift. As a 
consequence some of the Ro52 functions might be affected since it operates as E3 
ligase both in the cell cytoplasm and nucleus, according to our and other investigators 
results (paper IV, figure 1 and 2) [123, 129-131]. 
 
UVR induces iNOS, leading to NO production in human keratinocytes [52, 147]. NO, 
generated following skin exposure to UVR, contributes to the sunburn-induced 
inflammation including keratinocyte death [50, 52, 58]. In UVR-induced, developing 
CLE lesions the dynamics of iNOS expression has been demonstrated to be completely 
opposite to that observed in healthy controls: iNOS upregulation is delayed and 
observed only 2-3 days post-UVR, whereas in healthy individuals induction occurs 
within 24h and is resolved within 48h post-UVR. Concomitantly to increasing iNOS 
expression in the skin, numbers of apoptotic keratinocytes increases up to 72h post-
UVR [59, 62]. Induced NO might therefore contribute to the increased numbers of 
apoptotic keratinocytes observed in the CLE lesions. In papers III (figure 3 and 5) and 
IV (figure 6) we demonstrated nuclear and cytoplasmic staining of Ro52 in the 
spontaneous and UVR-induced CLE lesions. NO is commonly generated at the site of 
inflammation and Ro52 is upregulated at the active CLE lesions (paper III, figure 3 and 
5 and paper IV). These findings suggest that NO could be an important factor 
determining subcellular localization of Ro52 and consequently governing in what cell 
compartment Ro52 is operating as an E3 ligase.  
 
NO is an important mediator of inflammation. It is believed that NO has anti-
inflammatory properties at lower concentrations and is one of the essential molecules 
that can dull the responsiveness of the immune system to apoptotic cells [224]. Pro-
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inflammatory cytokines can induce substantial iNOS expression and subsequent NO 
synthesis, that may have the potential to further amplify inflammation [225]. 
Macrophages, when exposed to NO, initiate secretion of pro-inflammatory cytokines 
including HMGB1, TNF-Į and IL-1ȕ [226]. Moreover, these cytokines can further fuel 
inflammation by inducing iNOS and NO production [58, 148, 227, 228]. NO might 
thus contribute to ignition of a self-fueling pro-inflammatory loop observed in CLE 
[225] and, at high concentrations could contribute to the increased rate of keratinocyte 
apoptosis [229].  
 
5.4.4 Conclusion 
   
In paper IV we confirmed that Ro52 is predominately cell cytoplasm-located protein, 
but can fluctuate between the cell compartments. We demonstrated that the CC 
domain is important for the cytoplasmic accumulation and B30.2 for nuclear 
retention. The ability to shuttle between the nucleus and cytoplasm allows Ro52 to 
operate as E3 ligase and interact with E2s present in both cellular compartments. Our 
findings indicate that NO is able to modulate the cellular localization of Ro52. Under 
pro-inflammatory conditions Ro52 may need to convey both nuclear and cytoplasmic 
functions. According to our results, Ro52 is expressed in close proximity to iNOS and 
is located in the respective cellular compartments of the cells present in CLE skin 
lesions. 
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6 A HYPOTHESIS ON CLE/LE PATHOGENESIS 
The results of the studies included in this thesis contribute to a better understanding 
of the biological events occurring at the site of UVR-induced skin injury during CLE 
lesion development and healing. Taken together with the results of other investigators 
my data allows the suggestion of a hypothesis regarding the pathogenesis of LE 
(figure 7).  
Importantly, susceptibility to LE is inherited by multiple genes involved in regulation 
of the innate and adaptive immune responses. An external trigger of proinflammatory 
and/or cell-death inducing nature (e.g.UVR) is usually needed to induce clinical 
manifestation of the disease. The process of apoptosis and/or the response of the 
immune system to the presence of apoptotic cells is abnormal in at least a proportion 
of lupus-susceptible individuals [60]. Apoptotic cells are not cleared in the 
appropriate period of time and therefore accumulate [59]. Non-removed apoptotic 
cells usually undergo secondary necrosis and cannot longer withhold intracellular 
constituents, which are passively released to the surrounding [60]. An external trigger 
of a pro-inflammatory nature (e.g. UVR) that induces a local transient inflammatory 
response in a non-susceptible individual, may induce a stronger inflammatory 
reaction in an LE-susceptible person. Through activation of MyD88, NFțB and 
inflammasome, UVR stimulates keratinocytes to produce and secrete 
proinflammatory cytokines such as TNFĮ, IL-1ȕ, IL-6, IL-8 and probably HMGB1 
([50, 230] and paper II) (figure 7, I). Furthermore, synthesis of IFNs could also be 
initiated, but remains to be proved [64, 216]. In addition, our data indicate that UVR 
induces upregulation of the autoantigen Ro52 in keratinocytes (paper III). High Ro52 
expression might additionally increase keratinocyte sensitivity to the cell death-
inducing stimuli [123]. Dying keratinocytes that had upregulated Ro52 just before the 
death might release Ro52 and other autoantigens into the extracellular space together 
with highly pro-inflammatory and immunogenic nuclear material such as HMGB1 
tightly complexed with nucleosomes [115]. Circulating Igs and complement 
components opsonize the cell debris and build ICs that further promote inflammation, 
as in LE-susceptible individuals they cannot be efficiently removed due to the lack of 
complement components or phagocyte inability to recognize and engulf them [41, 
163, 165]. In such a proinflammatory environment chemokines (CXCL-9, -10, -11 
 54 
and -12) and adhesion molecules (ICAM1 and E-selectin) are upregulated and 
mediate leukocyte influx from the circulation [63]. These chemokines are expressed 
in the CLE lesions and home CXCR3 expressing cells that probably are activated 
effector T cells and pDCs and CXCR4 positive cutaneous DCs [89-91, 231]. The 
inflammatory infiltrates were demonstrated to be composed of CD4+ and CD8+ T 
cells, CD68+ macrophages and the majority of infiltrating cells express CXCR3. 
Granzyme B and Tia1 positive CTLs are also present in the lesions [90]. The 
presence of proinflammatory cytokines and ICs induces maturation of APCs. The ICs 
containing nuclear constituents might be recognized by pDCs and induce secretion of 
type I IFN, in particular IFNĮ [208, 232]. This cytokine has multiple effects on the 
immune system and is evolutionary directed to kill virus-infected cells; it is also 
activated in the major proportion of LE patients [63, 78, 143]. Importantly, Ro52 is 
an interferon-inducible protein and its upregulation, as observed in CLE lesions, 
might reflect the effect of presence of IFNs in the surrounding environment. In a 
mouse model with genetically disrupted Ro52, its absence, but not overexpression, 
leads to an uncontrollable inflammatory response to minor skin injury, which 
advances into lupus-like autoimmunity [131]. It is therefore possible that at least in 
some of LE patients Ro52, despite obvious upregulation, cannot convey its functions 
due to genetic polymorphisms in the Ro52 gene or that the present autoantibodies 
impede its function.  
Ro52, when released from secondary necrotic cells in a highly proinflammatory 
environment, in which matured APCs are present, might be taken up by DCs or 
recognized by activated B cells, which are otherwise anergic or low self-reactive. 
Subsequently the adaptive immune response against Ro52 could be initiated and 
autoantibodies generated (figure 7, II). The attack of the adaptive immune system on 
the target tissue via produced autoantibodies and activated effector T cells might 
further promote the vicious circle inducing cell death (figure 7, III). Escalating 
inflammation in a genetically susceptible individual might lead to cutaneous or even 
systemic manifestations of LE.  
To date, very little is known about factors predisposing to the development of one or 
another CLE subtype in a specific individual. The available data suggest some potential 
pathways. For example, the onset of SLE is usually preceded by arising titers of anti-
dsDNA autoantibodies, which are strongly associated with lupus nephritis (LN). The 
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pathogenesis of LN is associated with the deposition of ICs in the target tissue [9]. 
Accordingly, positive LBT, reflecting the deposition of ICs, can be detected in both 
ACLE involved and non-involved sun-protected skin of SLE patients and it therefore 
seems that ICs are randomly deposited in the skin [37]. Manifestation of facial ACLE is 
associated with sun exposure. It could be the case that a combination of sun-induced 
inflammation with simultaneous presence of the skin deposited ICs results in ACLE 
lesion development.  
 
SCLE is strongly associated with anti-Ro/SSA autoantibodies. Levels of anti-Ro52 
antibodies are usually higher than anti-Ro60 in these patients [15, 24]. Anti-Ro52 
autoantibodies are also related to NLE manifestations, such as congenital heart block 
and SCLE-like sun-induced/aggravated skin lesions. Importantly, the risk of NLE 
manifestations wanes after 6 months of age as maternal IgG, and anti-Ro/SSA, are 
clearing from the infant circulation [200]. It is therefore possible that anti-Ro/SSA 
mediate SCLE development after sun exposure even in adults.  
 
ITGAM gene has been demonstrated to confer higher risk to DLE rather than SLE 
[161]. This gene encodes a subunit of integrin-ĮM which is a subunit of type 3 
complement receptor (CR3) and could therefore influence leukocyte trafficking via 
ICAM-1. Integrin-ĮM could also account for the presence of dense cell infiltrates 
observed in DLE and could also affect the recognition and uptake of unviable cells and 
ICs via CR3 [41]. 
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 Figure 7. A hypothesis on CLE/LE pathogenesis 
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Figure 7. A hypothesis on CLE/LE pathogenesis.  
I. UVR-induced skin injury: a) activated keratinocytes secrete proinflammatory 
cytokines, express chemokines and upregulate Ro52 expression; b) cell cycle arrest due 
to UVR-induced DNA damage, possibility for DNA repair, but cell undergoes 
apoptosis if the damage is too extensive or the repair mechanisms fail; c) unremoved 
apoptotic keratinocytes undergo secondary necrosis and passively release intracellular 
constituents to the surrounding; d) macrophages and DCs are activated due to the 
presence of proinflammatory cytokines and unviable cells; e) DCs ingest cell debris 
and, probably, autoantigens. 
 
II. The initiation of the adaptive immune response against self: a) DCs present 
autoantigens to the cells of the adaptive immune system in the lymph node; b) cell 
influx to the site of UVR injury via upregulated adhesion molecules and chemokine 
gradient. 
 
III. Autoimmunity induced skin injury: 
a) unviable cell debris is opsonized by Igs and complement components. ICs are 
formed, maybe also Ro52-anti-Ro52; b) HMGB1-DNA-Ig activate pDCs and initiate 
IFNĮ secretion; c) cytotoxic and CD4+ effector T cells; d) HMGB1-DNA-Igs stimulate 
B cells. 
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7 CONCLUDING REMARKS 
 
The studies presented in this thesis provide new insights into which molecules are 
involved in the regulation of cutaneous inflammation in lupus erythematosus, and show 
that experimental photoprovocation is a reproducible, safe and valuable method to 
verify photosensitivity and study the pathogenesis of UVR-induced CLE.  
 
More specifically, we demonstrated that HMGB1 is upregulated and translocated to the 
extracellular space in UVR-induced CLE skin lesions, and that the highest expression 
of HMGB1 coincides with the peak of the clinical activity of the lesions. Expression 
patterns of TNF-Į and IL-1ȕ were not consistent, and in some patients expression was 
barely detectable. This fact emphasizes the importance of our findings regarding 
HMGB1 and prompts an idea that it may indeed be of major importance in the 
pathogenesis of CLE. Subsequent to publication of our study other investigators 
demonstrated that HMGB1 attached to nucleosomes is released from secondary 
necrotic cells. Our finding of extracellular HMGB1 within the epidermis and especially 
at the basal cell layer, where the majority of unviable cells are localized, might 
correspond to passively released HMGB1 from secondary necrotic cells. HMGB1 
bound to chromatin is highly proinflammatory and also autoantigenic. Such complexes, 
when distributed extracellularly in a proinflammatory environment, might activate cells 
of the immune system and contribute to breakage of immunological tolerance in a 
genetically susceptible individual. 
 
In papers III and IV we focused on the autoantigen Ro52. We determined its expression 
in the skin – a target organ of LE autoimmunity and defined factors that can modulate 
the cellular expression and localization of this autoantigen. Ro52 was strongly 
expressed in CLE lesions, in both keratinocytes and dermal-infiltrating cells, and in 
both keratinocyte cytoplasm and nucleus. Notably, similarly high Ro52 expression was 
observed in other inflammatory skin diseases not related to LE. Moreover, keratinocyte 
exposure to UVR upregulated its expression in the cytoplasm and NO induced its 
accumulation in the cell nucleus. We have also demonstrated that Ro52 in its capacity 
as an E3 ligase has both cytoplasmic and nuclear interaction partners, ubiquitin 
conjugating enzymes. In parallel to the studies included in the thesis, it was 
demonstrated that Ro52 interacts with IRFs and regulates inflammatory response. 
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Moreover, our group has developed an animal model with genetically disrupted Ro52. 
Intriguingly, loss of Ro52 resulted in uncontrollable systemic inflammation after minor 
skin injury that led to the development of lupus-like disease.  
 
A combination of findings that: 1) UVR induces upregulation of Ro52 in the 
keratinocytes that subsequently will die, but will not be removed efficiently; 2) Ro52 is 
upregulated in all CLE patients despite their subtype and anti-Ro52 autoantibody 
status; 3) similar strong Ro52 expression is observed in LE-nonrelated inflammatory 
skin diseases; 4) loss of Ro52, rather than its overexpression, leads to uncontrolled 
inflammation advancing to autoimmunity in an animal model;  allows me to propose 
the following hypothesis:  Ro52 is expressed in patients with CLE but cannot convey 
its function as a negative feedback regulator of inflammation. Ro52 is probably 
released by secondary necrotic keratinocytes in a proinflammatory environment and 
maybe that is how it is recognized by the adaptive immune system that subsequently 
initiates an autoimmune response against it in a genetically susceptible individual. 
More research is needed to investigate if this is indeed the case, and if so, identify the 
factors interfering with Ro52 and furthermore, determine how they can be defeated. 
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